WO2011069674A1 - Emulsifier-free, polymer-stabilized foam formulations - Google Patents

Emulsifier-free, polymer-stabilized foam formulations Download PDF

Info

Publication number
WO2011069674A1
WO2011069674A1 PCT/EP2010/007542 EP2010007542W WO2011069674A1 WO 2011069674 A1 WO2011069674 A1 WO 2011069674A1 EP 2010007542 W EP2010007542 W EP 2010007542W WO 2011069674 A1 WO2011069674 A1 WO 2011069674A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
emulsion
monomer
acids
foam formulation
Prior art date
Application number
PCT/EP2010/007542
Other languages
English (en)
French (fr)
Inventor
Rolf Daniels
Original Assignee
Neubourg Skin Care Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42144766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2011069674(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to ES10787327.5T priority Critical patent/ES2684304T3/es
Priority to BR112012012934-1A priority patent/BR112012012934B1/pt
Priority to CN2010800555999A priority patent/CN102652011A/zh
Priority to MX2012006619A priority patent/MX2012006619A/es
Priority to US13/514,687 priority patent/US9468590B2/en
Priority to EP10787327.5A priority patent/EP2509565B1/en
Priority to UAA201208487A priority patent/UA107003C2/uk
Application filed by Neubourg Skin Care Gmbh & Co. Kg filed Critical Neubourg Skin Care Gmbh & Co. Kg
Priority to PL10787327T priority patent/PL2509565T3/pl
Priority to KR1020127017936A priority patent/KR101835712B1/ko
Priority to JP2012542400A priority patent/JP2013513558A/ja
Priority to EA201200867A priority patent/EA026509B1/ru
Priority to CA2783121A priority patent/CA2783121C/en
Publication of WO2011069674A1 publication Critical patent/WO2011069674A1/en
Priority to IL220267A priority patent/IL220267A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/046—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/062—Oil-in-water emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/342—Alcohols having more than seven atoms in an unbroken chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • A61K8/8158—Homopolymers or copolymers of amides or imides, e.g. (meth) acrylamide; Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/817—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines (Polyquaternium 6)
    • A61K8/8182—Copolymers of vinyl-pyrrolidones. Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30—Characterized by the absence of a particular group of ingredients
    • A61K2800/33—Free of surfactant

Definitions

  • Emulsifier-free, polymer-stabilized foam formulations Technical field of the invention
  • the present invention relates to cosmetic and dermatological foam formulations, particularly to foam creams, based on emulsions of the oil-in-water type, which are free or substantially free of conventional emulsifiers and which comprise at least one surface active, ionic polymer with a molecular weight of more than 5000 g/mol, wherein the ionic polymer is a copolymer comprising as monomer units an ionic monomer and at least one further monomer.
  • emulsion relates to heterogeneous systems consisting of two liquids that are not miscible or only miscible to a limited extent, which are typically designated as phases.
  • one of the two liquids is dispersed in the other liquid in the form of minute droplets.
  • the emulsion is an oil-in-water emulsion (O W-emulsion, e.g. milk).
  • O W-emulsion oil-in-water emulsion
  • the basic character of an O/W-emulsion is defined by the water.
  • W/O-emulsion water-in-oil emulsion, e.g. butter
  • the opposite principle applies, wherein the basic character is in this case defined by the oil.
  • emulsions In order to obtain a durable dispersion of a liquid in another liquid, emulsions in a conventional sense require the addition of a surface active agent (emulsifier).
  • emulsifier emulsifier
  • Emulsifiers have an amphiphilic molecular structure consisting of a polar
  • one of the phases contains finely dispersed droplets of the second phase, which are enclosed by an emulsifier shell (water droplets in W/O-emulsions or lipid vesicles in O/W-emulsions).
  • Emulsifiers reduce the surface tension between the phases by being arranged at the interface between the two liquids. They form interfacial films at the oil/water phase interface which countervails the irreversible coalescence of the droplets.
  • mixtures of emulsifiers are often used.
  • emulsifier or "conventional emulsifier” is known in the art. Conventional emulsifiers and their use are described, e.g., in the publications: Vietnamesekosmetik, 4th edition,ticianliche Verlagsgesellschaft mbH Stuttgart, pages 151 to 159, and Fiedler Lexikon der Hilfsstoffe, 5th edition, Editio Cantor Verlag Aulendorf, pages 97 to 121. Conventional emulsifiers can be classified, based on the hydrophilic part of the molecule, into ionic (anionic, cationic and amphoteric) emulsifiers and non-ionic emulsifiers:
  • Important members of cationic emulsifiers are quaternary ammonium
  • the hydrophilic part of the molecule of non-ionic emulsifiers often consists of glycerol, polyglycerol, sorbitans, carbohydrates or polyoxyethylene glycols, and is most often connected by means of ester and ether bonds to the lipophilic part of the molecule.
  • the latter typically consists of fatty alcohols, fatty acids or iso-fatty acids.
  • emulsifiers The correct choice of the emulsifiers is decisive for the stability of an emulsion. In this respect, the characteristics of all substances contained in the system need to be considered. In case of skin care emulsions, for example, polar oil components such as e.g. UV filters may cause instabilities. Therefore, besides emulsifiers, other stabilizers are additionally used, which, e.g. increase the viscosity of the emulsion and/or act as protective colloid.
  • Emulsions represent an important type of product in the field of cosmetic and/or dermatological preparations, which is used in different areas of application.
  • a range of products - such as lotions and creams - are available for skin care, particularly for relubricating dry skin.
  • the aim of skin care is to compensate the loss of lipid and water caused by daily washing.
  • skin care products should protect from environmental stress - in particular from sun and wind - and delay skin aging.
  • Cosmetic emulsions are also used as deodorants. Such formulations serve for eliminating the odour of the body that is formed when fresh sweat, that as such is free of odour, is decomposed by microorganisms.
  • Emulsions in the form of cleaning emulsions are also used for the cleaning of the skin and skin adnexa. They are most often used for the cleaning of the face and especially for removing decorative cosmetics.
  • Such cleaning emulsions have the advantage - in contrast to other cleaning preparations such as soap - to be particularly skin compatible since they may contain in their lipophilic phase nurturing oils and/or non-polar active agents -such as, e.g., vitamin E.
  • Emulsifiers are surface active substances. They are preferably arranged in the interface between oil phase and water phase, and thereby reduce the surface tension. Even in low concentration, emulsifiers facilitate the formation of an emulsion. Moreover, these substances are able to enhance the stability of emulsions by reducing the rate of aggregation and/or coalescence.
  • genuine emulsifiers i.e. conventional emulsifiers in the sense of the present description
  • surfactants i.e. amphiphilic structure and the capability of micelle association.
  • Emulsifier-free emulsions are free of conventional emulsifiers, i.e. amphiphilic substances having a low molecular weight (i.e. molecular weight ⁇ 5000 g/mol), that, in suitable concentrations, can form micelles and/or other liquid crystalline aggregates.
  • emulsifier-free is established in the art. According to a definition of the Society for Dermopharmacy, which was adopted by an interdisciplinary consent among pharmacists, dermatologists and other experts
  • a formulation can be designated as "emulsifier-free” when it is stabilized by means of surface active macromolecules (molecular weight of above 5000 g/mol) instead of by emulsifiers in a narrower sense (i.e. conventional emulsifiers).
  • emulsifier-free emulsions are emulsions stabilized by solids.
  • Solid- stabilized emulsions which are known in the art as Pickering emulsions, are stabilized by means of finely dispersed solid particles and, as far as possible, allow for the abdication of conventional emulsifiers.
  • solids In solid-stabilized emulsions, solids accumulate at the oil/water phase interface in the form of a layer whereby the coalescence of the dispersed phase is prevented.
  • Suitable solid emulsifiers are in particular particulate, inorganic or organic solids, which are wettable by both hydrophilic and lipophilic liquids.
  • solid-stabilized emulsions or Pickering emulsions e.g. titanium dioxide, zinc oxide, silicon dioxide, Fe 2 0 3 , veegum, bentonite or ethyl cellulose are used as solid emulsifiers. 4.
  • a further example of emulsifier-free emulsions are polymer-stabilized emulsions.
  • the required stabilization is not achieved by amphiphilic, surfactant-like emulsifiers, but by means of suitable macromolecules.
  • the irritation potential of formulations that are stabilized in this way differs significantly from that of emulsions which are stabilized by conventional emulsifiers. Due to their high molecular mass, polymeric emulsifiers cannot penetrate into the stratum corneum. Therefore, undesired interactions, e.g. in the sense of Francisco acne, are not to be expected.
  • surface active macromolecules such as carbomer 1342 or hydroxypropyl methyl cellulose as primary emulsifiers is substantially more effective. These macromolecules form structured interfacial films that ensure an effective protection against coalescence. In this case, the increase of viscosity of the outer phase is of minor importance for the stability of the emulsions.
  • the structure of the interfacial film formed by polymeric emulsifiers can be generally described by the so-called tail-loop-train-model (see Myers D., Polymers at Interfaces, in Meyers D.: Surfaces, interfaces and colloids. VHC Publishers New York, pages 283-297, 1991), which is depicted schematically in Fig. 1.
  • Polymers can be used as emulsifiers in case they exhibit a sufficiently high surface activity.
  • Copolymers with a high molecular weight which contain, in addition to a hydrophilic monomer portion, a monomer portion with a lower polarity, are particularly suitable. Besides an increase in viscosity in the continuous water phase, they cause simultaneously and mainly a stabilization of the oil/water phase interface.
  • the portion having a lower polarity adsorbs to the oil phase and the hydrophilic structure swells in the aqueous phase to form a gel structure at the phase interface.
  • the gel structure formed by the strongly hydrated, hydrophilic polymer segments e.g. in the form of minute gel droplets along the oil/water phase interface, may provide an even more effective protection against coalescence than a non-gel-like interfacial film, as formed e.g. by hydroxypropyl methyl cellulose.
  • Carbomer 1342 is a copolymer of acrylic acid and Cio-C 30 alkyl acrylates, wherein the hydrophilic acrylic acid portion prevails the lipophilic alkyl acrylate portion.
  • the Cio-C 30 alkyl acrylates are additionally cross-linked by allyl pentaerithrol.
  • Particularly effective stabilizers for emulsifier-free oil-in-water emulsions are the diverse, commercially available copolymers of 2-acrylamido-2-methylpropane sulfonic acid.
  • 2-acrylamido-2-methylpropane sulfonic acid having the chemical formula (2)
  • X is H in the case of the free acid, is also called AMPS or 2-methyl-2-[(l- oxo-2-propenyl)amino]-l-propanesulfonic acid.
  • Its salts (wherein X + represents a cation other than H + ) are also called acryloyl dimethyltaurates.
  • AMPS 2-methyl-2-[(l- oxo-2-propenyl)amino]-l-propanesulfonic acid.
  • Its salts (wherein X + represents a cation other than H + ) are also called acryloyl dimethyltaurates.
  • Aristoflex® AVC and Aristoflex® HMB of the company Clariant are commercially available polymers Aristoflex® AVC and Aristoflex® HMB of the company Clariant.
  • Aristoflex® AVC (INCI name ammonium acryloyldimethyltaurate/vinylpyrrolidone copolymer) and Aristoflex® HMB (INCI name ammonium acryloyldimethyltaurate / beheneth-25 methacrylate crosspolymer) comprise an ionic monomer portion, 2- acrylamido-2-methylpropane sulfonic acid (AMPS), as well as a further, less polar monomer portion (vinylpyrrolidone or beheneth-25 methacrylate).
  • AMPS 2- acrylamido-2-methylpropane sulfonic acid
  • These polymers are used as thickener and as stabilizer for oil-in-water emulsions and form extremely stable emulsions already at low concentrations. In particular, these polymers can be used in conjunction with almost any oil phase, comprising silicone oils,
  • hydrocarbons/waxes and ester oils can be used over a wide pH range (Aristoflex® AVC: pH 4.0 to 9.0; Aristoflex® HMB: pH 3.0 to 9.0), and they are UV stable.
  • Copolymers of 2-acrylamido-2-methylpropane sulfonic acid are also offered and developed by the company Seppic as polymeric emulsifiers for emulsifier-free emulsions.
  • Seppic polymeric emulsifiers for emulsifier-free emulsions.
  • those are the commercially available product SepinovTM EMT 10 (INCI name hydroxyethyl acrylate/sodium acryloyldimethyltaurate copolymer, CAS-number 1 1 1286-86-3), as well as the experimental polymers 8732MP (product name: Sepinov P88, a sodium acrylate/ acryloyldimethyltaurate/
  • emulsifying properties are usable over a wide pH range (e.g. for SepinovTM EMT 10 pH 3-1 1), and are UV stable.
  • Aristoflex® AVC, Aristoflex® HMB, SepinovTM EMT 10 and the experimental Seppic-polymers 8732MP, 8885MP2 and 8947 MP are formulated in an already neutralized form, i.e. the 2-acrylamido-2-methylpropane sulfonic acid unit is present in the formulation at least partially as a salt, and they are in powder form.
  • Acryloyldimethyltaurate copolymers their manufacture, and their use as thickeners or stabilizers of emulsions for cosmetic and pharmaceutical applications are described for example in the publications EP 1 069 142 Al , EP 1 1 16 733 Al , WO 2008/087326 A2 and EP 1 138 703 Al .
  • WO 03/022236 Al describes the use of taurate copolymers, and in particular of Aristoflex® AVC, as thickener and stabilizer for cosmetic compositions, in particular for lotions and cream formulations, comprising Ci-C 25 alpha- or beta- hydroxycarboxylic acids.
  • a particular application form of cosmetic and/or dermatological emulsions is the application as foams.
  • Foam formulations have the advantage that they can be easily distributed on the skin. The foamy consistency is experienced as comfortable and the products normally leave a good skin feeling. In particular, the physical structure of the foam acts positively on the protective function of the skin. Foams are
  • foams are obtained by spraying an emulsion formulation or an aqueous surfactant (stabilizer) solution.
  • a emulsion charged with a propellant is dispensed from a pressurized container (in the literature and the patent literature such systems are also called aerosol foams).
  • the pressurized mixture of emulsion and propellant expands and forms the foam bubbles.
  • the dispersed oil phase in which the oil-soluble gas is dissolved, expands.
  • foams can also be formed by means of other systems such as, for example, pump sprays.
  • balanced foam formulations Upon application, balanced foam formulations have a stable two-phase or multiphase, polydisperse structure that forms on the skin a network structure which is comparable to a membrane.
  • Such network structures have the advantage that they develop a protective action, for example against contact with water, however, allow for the unhindered gas exchange with the environment.
  • perspiratio insensibiles there is practically no obstacle for the perspiratio insensibiles and no corresponding heat build-up. Thereby, the positive properties of a protective and nurturing action are combined with an unchanged perspiration.
  • conventional emulsifiers or surfactants are repeatedly cited as the cause of incompatibilities of skin care products. Nonetheless, the addition of suitable stabilizers is necessary, because disperse systems, as described above, e.g. emulsions, are thermodynamically instable.
  • the above described Pickering emulsions are an option to avoid conventional emulsifiers.
  • Pickering emulsions are described which are, however, used as emulsions in the form of lotions, creams and gels.
  • WO 2004/017930 further Pickering emulsions are described which are characterized especially by a low viscosity and, therefore, are suitable for dermatological cloths. Such thin fluid Pickering emulsions can even be sprayed under formation of a haze.
  • foam formulations on the basis of emulsifier-free Pickering emulsions are described.
  • WO 2008/155389 describes foam formulations on the basis of emulsions the oil phase of which comprises at least one membrane- forming substance forming in the foam formulation lamellar arranged membranes, wherein the emulsions are preferably emulsifier-free.
  • foam formulations on the basis of emulsifier-free emulsions, which are stabilized by ionic, surface active polymers with a molecular weight of more than 5000 g/mol, wherein the ionic polymer is a copolymer comprising as monomer units an ionic monomer (Ml) and at least one further monomer.
  • ionic polymer is a copolymer comprising as monomer units an ionic monomer (Ml) and at least one further monomer.
  • oil-in-water emulsions comprising at least one surface active, ionic polymer with a molecular weight of more than 5000 g/mol, wherein the ionic polymer is a copolymer, comprising as monomer units an ionic monomer (Ml) and at least one further monomer, are suitable as a basis for foam formulations.
  • the positive characteristics of foam formulations are combined with those of polymer-stabilized emulsions.
  • foam comprising at least one surface active, ionic polymer with a molecular weight of more than 5000 g/mol, wherein the ionic polymer is a copolymer, comprising as monomer units an ionic monomer (Ml) and at least one further monomer
  • formulations without conventional emulsifiers or with very low contents of conventional emulsifiers can be produced that combine the positive characteristics of the foam, namely the physical structure and the pleasant applicability, with the positive characteristics of polymer-stabilized emulsions, such as their good skin compatibility. This makes such foam formulations especially useful for cosmetic and dermatological formulations for sensitive skin types. Compatibility and user friendliness are advantageously combined.
  • the foaming of oil-in-water emulsions comprising at least one surface active, ionic polymer with a molecular weight of more than 5000 g/mol, wherein the ionic polymer is a copolymer, comprising as monomer units an ionic monomer (Ml) and at least one further monomer, results in stable foam products.
  • Foams are obtained, as already mentioned, e.g. by incorporating (pressure)liquefied propellants into O W-emulsion systems. When the propellant dissolved in the dispersed oil phase evaporates upon foaming, a foam (gas-in-liquid dispersion) is formed.
  • an oil-in-water emulsion comprising at least one surface active, ionic polymer with a molecular weight of more than 5000 g/mol, wherein the ionic polymer is a copolymer, comprising as monomer units an ionic monomer (Ml) and at least one further monomer, as well as at least one solid emulsifier, is a particularly suitable basis for foam formulations.
  • Foam formulations made thereof exhibit in particular an improved stability in comparison to the foam formulations known in the art which are made from Pickering emulsions, as well as to the above-mentioned, solely polymer-stabilized foam formulations.
  • the invention relates to foam formulations comprising a substantially emulsifier-free emulsion of the oil-in-water type, comprising an oil phase and an aqueous phase, the emulsion comprising at least one surface active, ionic polymer with a molecular weight of more than 5000 g/mol, wherein the ionic polymer is a copolymer, comprising as monomer units an ionic monomer (Ml) and at least one further monomer.
  • the foam formulations according to the invention further contain at least one solid emulsifier.
  • the invention relates to the use of a substantially emulsifier- free emulsion of the oil-in-water type, comprising an oil phase and an aqueous phase, the emulsion comprising at least one surface active, ionic polymer with a molecular weight of more than 5000 g/mol, wherein the ionic polymer is a copolymer, comprising as monomer units an ionic monomer (Ml) and at least one further monomer, for the manufacture of a foam formulation.
  • a substantially emulsifier- free emulsion of the oil-in-water type comprising an oil phase and an aqueous phase
  • the emulsion comprising at least one surface active, ionic polymer with a molecular weight of more than 5000 g/mol
  • the ionic polymer is a copolymer, comprising as monomer units an ionic monomer (Ml) and at least one further monomer, for the manufacture of a foam formulation.
  • the invention relates to the use of at least one surface active, ionic polymer with a molecular weight of more than 5000 g/mol, wherein the ionic polymer is a copolymer, comprising as monomer units an ionic monomer (Ml) and at least one further monomer, for the stabilization of foam formulations comprising a substantially emulsifier-free emulsion of the oil-in-water type.
  • ionic polymer is a copolymer, comprising as monomer units an ionic monomer (Ml) and at least one further monomer
  • the invention relates to the use of the foam formulations according to the invention as a carrier for active agents, as skin care agent, as skin cleaning agent or as sunscreen. Therefore, the foam formulation can be used for the manufacture of a cosmetic, a medical product or a pharmaceutical composition.
  • the invention comprises a method for the manufacture of foam
  • the method comprises the steps of: a) preparing an emulsion of the oil-in-water type b) filling the emulsion with a propellant into a pressurized
  • Figure 1 depicts the schematic structure of a macromolecular interfacial film according to the tail-loop-train-model.
  • Figure 2 depicts schematically the possible arrangements of a copolymeric emulsifier, depending on the distribution of the lipophilic and hydrophilic segments in case of A-B-block copolymers (A), A-B-A-block copolymers (B) and copolymers having a random distribution of hydrophilic segments and segments with lower polarity (C).
  • foam formulations are formulations, in particular emulsions, that are evidently adapted for the formation of a foam.
  • the formulations may be filled, either together with a (pressure)liquefied propellant into a pressurized container, or without propellant into a container other than a pressurized container that allows for the formation of a foam upon dispensing of the formulation/emulsion.
  • pump spray containers may be used.
  • substantially emulsifier-free emulsions are emulsions that contain less than 0.5 weight-%, preferably less than 0.3 weight-%, more preferably less than 0.1 weight-% and particularly preferred less than 0.05 weight-% of conventional emulsifiers.
  • emulsifier-free emulsions are emulsions that do not contain any conventional emulsifiers.
  • conventional emulsifiers according to the present invention are anionic, cationic, amphoteric and non-ionic surfactants.
  • anionic surfactants are neutralized branched and/or unbranched, saturated or unsaturated fatty acids having a chain length of 10 to 40 carbon atoms.
  • Typical representatives of cationic surfactants are ammonium compounds.
  • Typical representatives of non-ionic surfactants have a hydrophilic part of the molecule, such as glycerol, polyglycerol, sorbitan, carbohydrates or polyoxyethylene glycols, that is connected by means of ester and/or ether bonds to the lipophilic part of the molecule which typically consists of fatty alcohols, fatty acids or iso-fatty acids.
  • glycerol polyglycerol
  • sorbitan carbohydrates or polyoxyethylene glycols
  • carbohydrates or polyoxyethylene glycols that is connected by means of ester and/or ether bonds to the lipophilic part of the molecule which typically consists of fatty alcohols, fatty acids or iso-fatty acids.
  • polyethoxylated fatty acid esters having a chain length of 10 to 40 carbon atoms and a degree of ethoxylation of 5 to 100 belong to this group.
  • saturated and/or unsaturated, branched and/or unbranched fatty alcohols having a chain length of 10 to 40 carbon atoms belong to the group of non-ionic emulsifiers.
  • Conventional emulsifiers are often used in combinations.
  • Conventional emulsifiers in the sense of the present description are specified in the publications: Vietnamesekosmetik, 4th edition,ticianliche Verlagsgesellschaft mbH Stuttgart, pages 151 to 159 and Fiedler Lexikon der Hilfsscher, 5th edition, Editio Cantor Verlag Aulendorf, pages 97 to 121.
  • conventional emulsifiers according to the present invention are all amphiphilic substances with a molecular weight of ⁇ 5000 g/mol that, in higher concentration, may form micelles and/or other liquid crystalline aggregates.
  • conventional emulsifiers are all surface active substances that are present in the emulsion neither as solid nor as polymer, especially under conventional storage and application temperatures, such as e.g. room temperature.
  • fatty alcohols with a chain length of 10 to 40 carbon atoms fulfill the definition of a conventional emulsifier, as far as they are present in an emulsion, due to the formulation/composition thereof, not as a solid, but e.g. in liquid crystalline or dissolved form.
  • the fatty alcohols with a chain length of 10 to 40 carbon atoms are present in the emulsion as a solid, they do not fulfill the definition of a conventional emulsifier.
  • a solid emulsifier is a particulate substance that is wettable by both lipophilic and hydrophilic liquids.
  • Solid emulsifiers may be inorganic or organic solids. Furthermore, the particles may be untreated or coated.
  • the particle size is preferably between 1 nm and 200 nm, more preferably between 5 nm and 100 nm. In case of organic solid emulsifiers such as crystalline fatty acids, crystalline fatty acid esters or crystalline fatty alcohols, the particle size is preferably between 1 nm and 1000 nm.
  • a free acid or a free acid functional group is a compound with an acid function or an acid function, respectively, which is not neutralized to an extent of at least 98%, preferably at least 99% and particularly preferred of 100%.
  • a completely neutralized acid or a completely neutralized acid functional group is a compound with an acid function or an acid function, respectively, that is neutralized and present in the form of its salts to an extent of at least 98%, preferably at least 99% and particularly preferred of 100%.
  • a partially neutralized acid or a partially neutralized acid functional group is a compound with an acid function or an acid function, respectively, that is neutralized and present in the form of its salts to an extent of at least 2%, preferably at least 1%, and of at most 98%, preferably of at most 99%, while the non-neutralized fraction is present as a free acid.
  • stabilization of a foam formulation means that, due to the presence of an emulsifier polymer, in particular of a combination of the emulsifier polymer and a solid emulsifier, the structure of the foam formed from the foam formulation can be maintained for a longer period of time before the foam collapses, e.g. for a duration of at least 30 seconds, preferably at least 1 minute and particularly preferred of at least 2 minutes.
  • the expression "cyclic and linear N-vinyl carboxylic acid amides having a carbon chain of 2 to 9 carbon atoms” relates (i) in the case of cyclic amides to the number of carbon atoms in the cycle (e.g. in the case of N- vinylpyrrolidone the number of carbon atoms is 4), and (ii) in the case of linear amides to the chain length of the carboxylic acid moiety (e.g. in the case of N-vinyl acetamide, the respective number is 2).
  • foam formulations according to the present invention are based on a
  • substantially emulsifier- free emulsion of the oil-in-water type comprising an oil phase and an aqueous phase, wherein the emulsion comprises at least one surface active, ionic polymer with a molecular weight of more than 5000 g/mol.
  • the at least one surface active, ionic polymer with a molecular weight of more than 5000 g/mol is a copolymer comprising as monomer units an ionic monomer (Ml) and at least one further monomer.
  • Ml ionic monomer
  • emulsifier-copolymers such polymers are also referred to as emulsifier-copolymers.
  • the oil-in-water emulsion further comprises at least one solid emulsifier.
  • the emulsion does not comprise any conventional emulsifiers.
  • the foam formulations according to the present invention comprise an emulsion of the oil-in-water type, comprising an oil phase and an aqueous phase, wherein the emulsion comprises an emulsifier system, the emulsifier system consisting substantially of: a) at least one solid emulsifier, and
  • ionic polymer with a molecular weight of more than 5000 g/mol, wherein the ionic polymer is a copolymer, comprising as monomer units an ionic monomer (Ml), and at least one further monomer.
  • the expression "emulsifier system consisting substantially of means that the emulsifier system may contain, if applicable, small amounts of conventional emulsifiers. However, the amount of conventional emulsifiers must then be low enough that the emulsion comprising the emulsifier system is a "substantially emulsifier-free emulsion" according to the present invention.
  • the emulsifier system consists of the at least one solid emulsifier and the at least one emulsifier-(co)polymer. Apart from the emulsifiers of the emulsifier system, the oil-in-water emulsion on which the foam formulation is based does not comprise any further emulsifiers.
  • the at least one surface active, ionic polymer with a molecular weight of more than 5000 g/mol may be described as a polymer that stabilizes the emulsion by the formation of a gel structure at the oil/water phase interface.
  • emulsifier polymers may be anionic, cationic or zwitterionic.
  • the gel structure formed at the oil/water phase interface is present in the form of a layer of gel droplets surrounding the oil phase, wherein the gel droplets are preferably strongly hydrated.
  • the presence of such gel structures can be proved by interfacial-rheology measurements.
  • the surface active, ionic polymer which stabilizes the emulsion by the formation of a gel structure at the oil/water phase interface additionally acts as thickener, i.e. besides the formation of a gel structure at the oil/water phase interface, the viscosity of the surrounding aqueous phase is also increased.
  • the gel structure at the oil/water phase interface preferably has a higher viscosity than the aqueous phase surrounding the gel structure.
  • the at least one surface active, ionic polymer with a molecular weight of more than 5000 g/mol which stabilizes the emulsion by formation of a gel structure at the oil/water phase interface, is a copolymer comprising as monomer units an ionic monomer (Ml) and at least one further monomer (i.e. is an emulsifier-copolymer).
  • the at least one surface active, ionic polymer with a molecular weight of more than 5000 g/mol is preferably water-soluble or water swellable, particularly preferred water swellable.
  • water swellable means that upon contact with water, the polymer hydrates accompanied by a volume increase.
  • the emulsion contains the at least one surface active, ionic polymer with a molecular weight of more than 5000 g/mol in an amount of approximately 0.01 to approximately 10 weight-%, preferably of approximately 0.05 to approximately 8 weight-%, more preferably of approximately 0.1 to approximately 5 weight-%, particularly preferred of approximately 0.2 to approximately 2 weight-%, and most preferred of approximately 0.2 to approximately 1 weight-%, based on the total weight of the emulsion (without propellant).
  • a molecular weight of more than 5000 g/mol in an amount of approximately 0.01 to approximately 10 weight-%, preferably of approximately 0.05 to approximately 8 weight-%, more preferably of approximately 0.1 to approximately 5 weight-%, particularly preferred of approximately 0.2 to approximately 2 weight-%, and most preferred of approximately 0.2 to approximately 1 weight-%, based on the total weight of the emulsion (without propellant).
  • Emulsifier-copolymers are Emulsifier-copolymers:
  • the emulsifier-copolymers used according to the present invention contain as monomer units an ionic monomer (Ml) and at least one further monomer.
  • the at least one further monomer is different from the ionic monomer (Ml).
  • An emulsifier-copolymer which contains one further monomer is a bipolymer, in the case of two further monomers it is a terpolymer, etc.
  • bipolymers, terpolymers, quaterpolymers, etc. are all comprised by the term copolymer.
  • copolymers containing intramolecular cross- linkages are referred to as cross-linked copolymers or cross-polymers.
  • the at least one further monomer has a different polarity than the ionic monomer (Ml).
  • Ml ionic monomer
  • polarity shall be understood according to its usual meaning in the technical field. Polarity refers to a bond of separated charges, caused by a shift of charges in atomic groups, resulting in the atomic group being no longer electrically neutral. The electric dipole moment is a measure for the polarity of a molecule.
  • the further monomer has a different polarity than the ionic monomer (Ml) if it is a non-ionic monomer which has, by definition, a lower polarity than an ionic compound.
  • the further monomer of different polarity may also be an ionic monomer. If the latter contains besides its ionic functionality, e.g. a long, hydrophobic fatty acid chain, it may overall have a smaller polarity than an ionic monomer (Ml), which does not contain a hydrophobic part.
  • the at least one further monomer is preferably selected from the group consisting of ionic monomers, non-ionic monomers and mixtures thereof. Particularly preferred, the at least one further monomer comprises at least one non-ionic monomer.
  • the ionic monomer (Ml) is preferably anionic, cationic or zwitterionic, particularly preferred anionic.
  • the ionic monomer (Ml) contains free, partially neutralized or completely neutralized acid functional groups.
  • a monomer containing free acid functional groups is to be understood as ionic monomer because the acid functional groups may be at least partially neutralized either during the manufacture of the copolymer or during the manufacture of the oil-in-water emulsion.
  • the acid functional groups are preferably selected from the group consisting of sulfonic acid groups, carboxylic acid groups, phosphoric acid groups, phosphonic acid groups and mixtures thereof.
  • the ionic monomer (Ml) is selected from the group consisting of acrylic acids, methacrylic acids, crotonic acids, maleic acids, fumaric acids, styrene sulfonic acids, vinyl sulfonic acids, vinyl phosphonic acids, allyl sulfonic acids, methallyl sulfonic acids, acrylamido alkylsulfonic acids, which may each be present as free acid, partially or completely neutralized in the form of their salts, preferably the alkali metal salts, alkaline-earth metal salts, ammonium salts or alkanol ammonium salts; or as anhydride, and mixtures thereof.
  • the ionic monomer (Ml) is selected from the group consisting of acrylic acids, methacrylic acids, and acrylamido alkylsulfonic acids.
  • the ionic monomer (Ml) is preferably an acrylamido alkylsulfonic acid, such as 2- acrylamido-2-methylpropane sulfonic acid.
  • the acrylamido alkylsulfonic acid is present partially or completely neutralized as alkali metal salt, alkaline-earth metal salt, ammonium salt or alkanol ammonium salt, particularly preferred as sodium or ammonium salt, most preferred as ammonium salt.
  • the acrylamido alkylsulfonic acid has the general formula (1), wherein R ⁇ is selected from the group consisting of hydrogen, methyl or ethyl, Z is a (Ci-C 8 )-alkylene, that may be unsubstituted or substituted with one or more (C 1 -C4)- alkyl groups, and X + is selected from the group consisting of H + , an alkali metal ion, an alkaline-earth metal ion, an ammonium ion, an alkanol ammonium ion, or mixtures thereof.
  • X + is selected from the group consisting of H + , Na + , NH 4 + , or mixtures thereof.
  • the acrylamido alkylsulfonic acid or the ionic monomer (Ml) is 2-acrylamido-2-methylpropane sulfonic acid (AMPS, 2-methyl-2-[(l -oxo-2-propenyl)amino]-l-propanesulfonic acid), having the chemical formula (2),
  • X is H
  • X + is a cation except H + , e.g. an alkali metal ion such as Na + , an alkaline-earth metal ion such as (1/2) Ca 2+ , or an ammonium ion, such as NH 4 + ).
  • X + is selected from the group consisting of H + , Na + , NH 4 + , or mixtures thereof.
  • the ionic monomer (Ml) is sodium acryloyldimethyltaurate or ammonium acryloyldimethyltaurate (X is Na + and NH 4 + , respectively).
  • the ionic monomer (Ml) is an acrylic acid and/or a methacrylic acid.
  • the at least one further monomer comprises at least one non- ionic monomer, preferably selected from the group consisting of styrenes, chlorostyrenes, di-(Ci-C 30 )-alkylamino styrenes, vinyl chlorides, isoprenes, vinyl alcohols, vinyl methyl ethers, (Ci-C 30 )-carboxylic acid vinyl esters, preferably vinyl acetates and vinyl propionates; acrylic acid esters, methacrylic acid esters, maleic acid esters, fumaric acid esters, crotonic acid esters; in particular linear and branched (Ci-C 3 o)-alkyl esters of acrylic acid, methacrylic acid, maleic acid, fumaric acid and crotonic acid; linear and branched (Ci-C 3 o)-hydroxyalkyl esters of acrylic acid, methacrylic acid, maleic acid, fumaric acid and crotonic acid; ethoxylated (C
  • the at least one further monomer may also comprise at least one ionic monomer, preferably selected from the group consisting of acrylic acids, methacrylic acids, crotonic acids, maleic acids, fumaric acids, styrene sulfonic acids, vinyl sulfonic acids, vinyl phosphonic acids, allyl sulfonic acids, methallyl sulfonic acids, acrylamido alkylsulfonic acids, which may each be present as free acid, partially or completely neutralized in the form of their salts, preferably the alkali metal salts, alkaline-earth metal salts or ammonium salts; or as anhydride, and mixtures thereof.
  • ionic monomer preferably selected from the group consisting of acrylic acids, methacrylic acids, crotonic acids, maleic acids, fumaric acids, styrene sulfonic acids, vinyl sulfonic acids, vinyl phosphonic acids, allyl sulfonic acids, methallyl
  • the at least one further monomer comprises an acrylic acid, that is present partially or completely neutralized in the form of its alkaline metal salt, alkaline-earth metal salt or ammonium salt.
  • the at least one further monomer comprises sodium acrylate.
  • a particularly suitable emulsifier-copolymer is for example sodium acrylate/sodium acryloyldimethyltaurate copolymer, in particular in the form of the product available from the company Seppic under the designation 8885MP2 (Sepinov EG-P).
  • Another particularly suitable emulsifier-copolymer is sodium acrylate/sodium acryloyldimethyltaurate copolymer, in particular in the form of the product available from the company Seppic under the designation 8885MP2 (Sepinov EG-P).
  • Another particularly suitable emulsifier-copolymer is sodium acrylate/
  • acryloyldimethyltaurate/ dime hylacrylamide crosspolymer in particular in the form of the product available from the company Seppic under the designation 8732MP (Sepinov P88).
  • a further particularly suitable emulsifier-copolymer is hydroxyethyl acrylate/ sodium acryloyldimethyltaurate copolymer, particularly in the form of the product ropeted by the company Seppic under the trade name SepinovTM EMT 10.
  • a particularly suitable emulsifier-copolymer is acryloyldimethyltaurate/
  • vinylpyrrolidone copolymer preferably ammonium acryloyldimethyltaurate/ vinylpyrrolidone copolymer, in particular in the form of the product marketed under the trade name Aristoflex® AVC.
  • Acryloyldimethyltaurate/ vinylpyrrolidone copolymer has preferably the general formula (3)
  • the polymer is preferably a statistical coplymer, a block copolymer or a graft copolymer, particularly preferred a statistical coplymer.
  • the at least one further monomer is preferably selected from the group consisting of cyclic and linear N-vinyl carboxylic acid amides having a carbon chain of 2 to 9 carbon atoms, linear and branched (Ci-C 30 )- alkyl esters of acrylic acid, linear and branched (Ci-C 3 o)-alkyl esters of methacrylic acid, linear and branched (Ci-C 30 )-hydroxyalkyl esters of acrylic acid, linear and branched (Ci-C 3 o)-hydroxyalkyl esters of methacrylic acid, and mixtures thereof.
  • the at least one further monomer may be selected from the group consisting of cyclic and linear N-vinyl carboxylic acid amides having a carbon chain of 2 to 9 carbon atoms, linear and branched (Ci-C 6 )-alkyl esters of acrylic acid, linear and branched (Ci-C 6 )-alkyl esters of methacrylic acid, and mixtures thereof.
  • the ionic monomer (Ml) is acrylic acid
  • the at least one further monomer is a cyclic or linear N-vinyl carboxylic acid amide having a carbon chain of 2 to 9 carbon atoms.
  • the cyclic or linear N-vinyl carboxylic acid amides mentioned above are preferably selected from the group consisting of N-vinyl pyrrolidone, N-vinyl caprolactame, N- vinyl acetamide, or N-vinyl-N-methylacetamide.
  • N-vinyl carboxylic acid amide having a carbon chain of 2 to 9 carbon atoms is N-vinyl pyrrolidone.
  • a particularly suitable emulsifier-copolymer in this regard is for example acrylic acid/ N-vinyl pyrrolidone copolymer, in particular in the form of the product UltraThix P-100 (INCI-name: acrylic acid/VP Crosspolymer).
  • UltraThix P-100 which is a lightly crosslinked copolymer of vinyl pyrrolidone and acrylic acid is marketed by the company ISP.
  • the weight ratio of acrylic acid to N-vinyl pyrrolidone in the acrylic acid N-vinyl pyrrolidone copolymer may preferably be in the range of 1 :3 to 3:1 , more preferably of 1 :2 to 2: 1 , most preferably is equal to 1 : 1.
  • the ionic monomer (Ml) is methacrylic acid and the at least one further monomer is selected from one or more, linear or branched (Ci-C 6 )-alkyl esters of acrylic acid or methacrylic acid, preferably from one or more linear or branched (Ci-C 6 )-alkyl esters of acrylic acid, more preferably from one or more of methyl acrylate, ethyl acrylate, n-propyl acrylate, i-propyl acrylate, n-butyl acrylate, i-butyl acrylate, tert-butyl acrylate, and mixtures thereof.
  • a particularly suitable emulsifier-copolymer in this regard is for example a terpolymer of tert-butyl acrylate, ethyl acrylate and methacrylic acid, in particular in the form of the product Luvimer® 100 P (INCI-name: Acrylates copolymer).
  • a copolymer of acrylic acid and a cyclic or linear N-vinyl carboxylic acid amide having a carbon chain of 2 to 9 carbon atoms such as acrylic acid/ N-vinyl pyrrolidone copolymer and
  • the at least one surface active, ionic polymer comprises acrylic acid/ N-vinyl pyrrolidone copolymer and/or tert-butyl acrylate/ ethyl acrylate/ methacrylic acid terpolymer.
  • the at least one surface active, ionic polymer is preferably selected from the group consisting of
  • acryloyldimethyltaurate copolymer acrylic acid/ N-vinyl pyrrolidone copolymer, tert-butyl acrylate/ ethyl acrylate/ methacrylic acid terpolymer, and mixtures thereof.
  • the emulsifier-copolymers are used in pre-neutralized form, wherein they are preferably in powder form.
  • the emulsifier-copolymers may at least be partially neutralized during the production of the emulsion, e.g. by adjusting the pH of an aqueous phase containing the emulsifier-copolymer.
  • the weight ratio between the ionic monomer (Ml) and the at least one further monomer is from 99: 1 to 1 :99, preferably from 95:5 to 5:95, particularly preferred from 90: 10 to 10:90.
  • the emulsifier-copolymer may be for example a statistical coplymer, a block copolymer or a graft copolymer or mixtures thereof, wherein statistical coplymers are preferred.
  • the emulsifier-copolymer is cross- linked, wherein the crossed-linked emulsifier-copolymer contains preferably from 0.001 to 10 weight-%, particularly preferred 0.01 to 10 weight-% of crosslinking agent.
  • crosslinking agents may be used for example diallyloxyacetic acid or its salts, trimethylolpropanetriacrylate, trimethylolpropane diallyl ether, ethylene glycol dimethacrylate, diethylene glycol diacrylate, tetraethylene glycol diacrylate, methylene bis(acrylamide), divinylbenzene, diallyl urea, triallylamine, 1 ,1 ,2,2- tetraallyloxyethane, acrylic acid allyl ester, methacrylic acid allyl ester,
  • dipropyleneglycol diallyl ether polyglycol diallyl ether, triethyleneglycol divinylether, or hydrochinone diallyl ether.
  • suitable crosslinking agents comprise pentaerythritol triallylether, pentaerythritol triacrylate, or pentaerythritol tetraacrylate.
  • the at least one surface active, ionic polymer comprises a linear acrylic acid N-vinyl pyrrolidone copolymer, which is crosslinked with 0,5 to 1 ,5 weight-%, preferably with about 1 weight-%) of pentaerythritol triallylether.
  • Solid emulsifiers :
  • the emulsion contains at least one solid emulsifier, preferably in an amount of more than 0.5 weight-%, particularly preferred more than 1 weight-%.
  • the emulsion contains from 0.5 to 7 weight-%, preferably from 0.5 to 5 weight-%, particularly preferred from 0.5 to 3 weight-% of the at least one solid emulsifier.
  • the weight percentages are each based on the total weight of the emulsion without propellant.
  • the weight ratio of the at least one solid emulsifier to the at least one ionic, surface active polymer in the emulsion is preferably from 0.5: 1 to 10:1 , more preferably from 1 : 1 to 8: 1 , and particularly preferred from 2: 1 to 8: 1.
  • Suitable solid emulsifiers are particulate inorganic or organic solids that are wettable by both lipophilic and hydrophilic liquids. Suitable representatives are e.g. titanium dioxide, in particular coated titanium dioxide (e.g. obtainable from Merck KGaA under the designation Eusolex® T-2000), zinc oxide (e.g.
  • silicon dioxide in particular highly dispersed silicon dioxide, Fe 2 0 3; veegum, bentonite and ethyl cellulose.
  • aluminium oxide, calcium carbonate, coal, magnesium oxide, magnesium trisilicate, crystalline fatty acids, crystalline fatty acid esters, crystalline fatty alcohols, polymer lattices, e.g. polystyrenes or polymethacrylates and polymer-pseudolattices may be used. Mixtures of the above-mentioned solid emulsifiers may also be used.
  • the at least one solid emulsifier is selected from the group consisting of crystalline fatty acids, crystalline fatty acid alkyl esters, crystalline fatty alcohols or mixtures thereof.
  • the at least one solid emulsifier comprises a crystalline fatty acid, preferably with a chain length of 10 to 40 carbon atoms.
  • the crystalline fatty acid is in particular a saturated fatty acid, preferably selected from the group consisting of myristic acid, palmitic acid, margaric acid, stearic acid and arachidic acid or mixtures thereof.
  • the at least one solid emulsifier comprises stearic acid.
  • Stearic acid is available for example from the company Cognis under the name Cutina FS 45.
  • the at least one solid emulsifier may comprise a crystalline fatty alcohol, preferably with a chain length of 10 to 40 carbon atoms.
  • the crystalline fatty alcohol is in particular a saturated fatty alcohol, preferably selected from the group consisting of myristyl alcohol, cetyl alcohol, heptadecanol, stearyl alcohol, cetylstearyl alcohol, eicosanol or mixtures thereof.
  • the at least one solid emulsifier comprises cetylstearyl alcohol.
  • the cetylstearyl alcohol is available for example from the company Cognis under the name Lanette O.
  • the at least one solid emulsifier may comprise a crystalline fatty acid alkyl ester, preferably cetyl palmitate.
  • Cetyl palmitate is available for example from the company Cognis under the name Cutina CP. Oil phase:
  • Suitable components that may form the oil phase may be selected from polar and non-polar oils or mixtures thereof.
  • the oil phase of the inventive formulations is advantageously selected from the group of phospholipids, such as lecithin and fatty acid triglycerides, from the group of propylene glycol fatty acid esters or butylene glycol fatty acid esters, from the group of natural waxes of animal or plant origin, from the group of ester oils, from the group of dialkyl ethers and dialkyl carbonates, from the group of branched and unbranched hydrocarbons and waxes as well as from the group of cyclic and linear silicon oils.
  • phospholipids such as lecithin and fatty acid triglycerides
  • propylene glycol fatty acid esters or butylene glycol fatty acid esters from the group of natural waxes of animal or plant origin, from the group of ester oils, from the group of dialkyl ethers and dialkyl carbonates, from the group of branched
  • the oil phase comprises at least one fatty acid alkyl ester such as oleic acid decyl ester (decyl oleate) or cetearyl isononanoate, and/or at least one fatty alcohol such as 2-octyldodecanol.
  • the oil phase may contain saturated aliphatic hydrocarbons such as paraffin.
  • Decyl oleate is obtainable for example from the company Cognis under the designation Cetiol V.
  • Cetearyl isononanoate is obtainable for example from the company Cognis under the designation Cetiol SN.
  • 2-Octyldodecanol is obtainable for example from the company Cognis under the designation Eutanol G.
  • the oil phase comprises at least one triglyceride.
  • the at least one triglyceride comprises caprylic acid/capric acid triglyceride obtainable under the designation Miglyol 812 of the company Sasol, and mixtures thereof with further oil and wax components.
  • triglycerides in particular caprylic acid/capric acid triglyceride obtainable under the designation Miglyol 812 of the company Sasol/Myritol 312 of the company Cognis.
  • the emulsions according to the invention preferably contain from 5 to 50 weight-% oil phase, particularly preferred 10 to 35 weight-% and especially preferred 12 to 25 weight-% oil phase. These values each refer to the total weight of the emulsion without propellant.
  • Aqueous phase Aqueous phase:
  • the aqueous phase may contain cosmetic adjuvants, e.g. lower alcohols (e.g. ethanol, isopropanol), lower diols or polyols as well as ethers thereof (e.g. propylene glycol, glycerol, butylene glycol, hexylene glycol and ethylene glycol), foam stabilizers and thickeners.
  • cosmetic adjuvants e.g. lower alcohols (e.g. ethanol, isopropanol), lower diols or polyols as well as ethers thereof (e.g. propylene glycol, glycerol, butylene glycol, hexylene glycol and ethylene glycol), foam stabilizers and thickeners.
  • Suitable thickeners are polymeric thickeners that are partially water soluble or at least water dispersible and that form in aqueous systems gels or viscous solutions. They increase the viscosity of the water either by binding water molecules
  • Suitable polymers are:
  • cellulose ethers e.g. hydroxypropyl cellulose ether, hydroxyethyl cellulose and hydroxypropyl methyl cellulose ether
  • cellulose ethers e.g. hydroxypropyl cellulose ether, hydroxyethyl cellulose and hydroxypropyl methyl cellulose ether
  • Natural compounds such as e.g. xanthan, agar-agar, carrageen, polyoses, starch, dextrines, gelatine, casein;
  • Synthetic compounds such as e.g. vinyl polymers, polyethers, polyimines, polyamides and derivates of polyacrylic acid; and
  • the emulsion contains at least one thickener selected from the group consisting of hydroxypropyl methyl cellulose, xanthan gum, sodium polyacrylate and mixtures thereof.
  • a preferred hydroxypropyl methyl cellulose according to the invention is Metolose 90SH 100.
  • the general pharmacopoeial term for hydroxypropyl methyl cellulose is hypromellose.
  • Xanthan gum is available for example from the company Kelco under the
  • Keltrol® CG Sodium polyacrylate is available for example from the company Cognis under the designation Cosmedia SP.
  • the emulsions according to the invention preferably contain from 0.2 to 1.5 weight- % of thickener (based on the dry weight of the thickener and the total weight of the emulsion without propellant). Particularly preferred are 0.2 to 0.8 weight-% of thickener. In a further preferred embodiment, the emulsions according to the present invention do not contain polyacrylate (homopolymer) as thickener.
  • the optionally contained active agent may be selected from all active agents that can be applied to the surface of the skin, and mixtures thereof.
  • the active agent may act cosmetically or pharmaceutically. Accordingly, cosmetic or dermatological (to be employed as medical product or pharmaceutical composition) foam formulations are obtained. Furthermore, the formulation may be used for protecting the skin against environmental influences.
  • the active agent can be of natural or synthetic origin.
  • the group of active agents may also overlap with other groups of ingredients, such as e.g. the oil component, the thickening agents or the solid emulsifiers.
  • some oil components may also act as active agents, such as e.g. oils having
  • polyunsaturated fatty acids such as e.g. particulate titanium dioxide may serve as UV-filter.
  • solid emulsifiers such as e.g. particulate titanium dioxide may serve as UV-filter.
  • the substances can be assigned to several groups.
  • Active agents of the inventive formulations are advantageously selected from the group of substances having moisturizing and barrier-strengthening properties, such as e.g. Hydroviton, an emulation of NMF, pyrrolidone carboxylic acid and salts thereof, lactic acid and salts thereof, glycerol, sorbitol, propylene glycol and urea, substances from the group of proteins and protein hydrolysates, such as e.g. collagen, elastin as well as silk protein, substances of the group of glucosaminoglucanes, such as e.g. hyaluronic acid, of the group of carbohydrates, such as e.g.
  • substances having moisturizing and barrier-strengthening properties such as e.g. Hydroviton, an emulation of NMF, pyrrolidone carboxylic acid and salts thereof, lactic acid and salts thereof, glycerol, sorbitol, propylene glycol and urea
  • Pentavitin that corresponds in respect of its composition to the carbohydrate mixture of the human corneal layer, and the group of lipids and lipid precursors such as for example ceramides.
  • Further advantageous active agents in the sense of the present invention may further be selected from the group of vitamins, such as e.g. panthenol, niacin, ct- tocopherol and its esters, vitamin A as well as vitamin C.
  • active agents selected from the group of antioxidants e.g. galates and polyphenols may be used.
  • Urea, hyaluronic acid and Pentavitin are preferred substances.
  • substances having skin soothing and regenerative action are employed as active agents, such as e.g. panthenol, bisabolol and phytosterols.
  • the foam formulation according to the invention contains urea.
  • the foam formulation according to the invention contains no a- or ⁇ -hydroxycarboxylic acids or salts thereof, in particular no Ci-C 25 -a- or Ci-C 25 - -hydroxycarboxylic acids or salts thereof.
  • Advantageous active agents in the sense of the present invention are also plants and plant extracts. These include e.g.
  • algae aloe, arnica, barber's rash, comfrey, birch, nettle, calendula, oak, ivy, witch-hazel, henna, hop, camomile, ruscus, peppermint, marigold, rosemary, sage, green tea, tea tree, horsetail, thyme and walnut as well as extracts thereof.
  • the formulations according to the invention may further contain as active agents antimycotics and antiseptics/disinfectants of synthetic or natural origin.
  • Further active agents are glucocorticoids, antibiotics, analgetics, antiphlogistics, antirheumatics, antiallergics, antiparasitics, antipruriginostics, antipsoriatics, retinoids, local anaesthetics, therapeutic agents for veins, ceratolytics, hyperaemic substances, coronary therapeutic agents (nitrates/nitro-compounds), antiviral drugs, cytostatics, hormones, agents promoting wound healing, e.g. growth factors, enzyme preparations and insecticides.
  • the formulations may optionally contain colouring agents, pearlescent pigments, fragrances/perfum, sunscreen filter substances, preservatives, complex formers, antioxidants and repellent agents as well as pH-regulators.
  • the formulations according to the invention are free of substances that may irritate the skin and are in particular free of fragrances/perfum, colouring agents and conventional emulsifiers.
  • the foam formulations according to the invention may contain, apart from the components already described above, further natural fats such as e.g. shea butter, neutral oils, olive oil, squalane, ceramides and moisturing substances as usual in the art.
  • further natural fats such as e.g. shea butter, neutral oils, olive oil, squalane, ceramides and moisturing substances as usual in the art.
  • Suitable propellants are e.g. N 2 0, propane, butane and i-butane.
  • the complete foam formulation contains for example from 1 to 20 weight-%, from 2 to 18 weight-% or from 5 to 15 weight-%, preferably approximately 10 weight-% of propellant.
  • the foam formulations according to the invention are prepared by providing an emulsion of the oil-in-water type and filling said emulsion and optionally charging with a propellant into a suitable container, preferably into a pressurized container.
  • a propellant and a pressurized container the polymer-stabilized emulsion may also be filled into a different container that is suitable to dispense the emulsion as a foam even in the absence of propellant.
  • Such systems are known to the person skilled in the art.
  • the method for manufacturing the emulsion comprises the following steps:
  • ionic polymer with a molecular weight of more than 5000 g/mol, wherein the ionic polymer is a copolymer, comprising as monomer units
  • the liquid oil phase of step (1) is provided in the form of a clear melt, preferably by heating to a temperature of from 60 to 90 °C, particularly preferred of from 60 to 80 °C, most preferred of approximately 70 °C, and is optionally subsequently cooled to the temperature used in step (3).
  • the mixing and the homogenizing of the aqueous phase with the oil phase in step (3) is performed at a temperature of from 25 to 60 °C, more preferably of from 30 to 50 °C, particularly preferred of from 35 to 45 °C, and most preferred of approximately 40°C.
  • the liquid oil phase provided in step (1) preferably contains at least one solid emulsifier. If the polymer-stabilized emulsion comprises at least one thickener, the oil phase provided in step (1) preferably contains at least one thickener, and/or the aqueous phase provided in step (2) preferably contains at least one thickener, and/or the method preferably comprises the following further steps:
  • the method of manufacturing the polymer-stabilized emulsion comprises the following steps:
  • the liquid oil phase of step (1) is provided in the form of a clear melt, preferably by heating to a temperature of from 60 to 90 °C, particularly preferred of from 60 to 80 °C, and most preferred of approximately 70 °C, and is optionally subsequently cooled to the temperature used in step (3).
  • the mixing and homogenizing of the aqeous phase with the oil phase in step (3) is performed at a temperature of from 25 to 60 °C, more preferably of from 30 to 50 °C, particularly preferred of from 35 to 45 °C, and most preferred of approximately 40°C.
  • the mixing of the further aqueous phase with the emulsion of step (5) is performed at a temperature of from 10 to 30°C, preferably of from 15 to 25°C and particularly preferred at room temperature.
  • the liquid oil phase provided in step (1) preferably contains at least one solid emulsifier.
  • the oil phase provided in step (1) preferably contains at least one thickener
  • the aqueous phase provided in step (2) preferably contains at least one thickener
  • the further aqueous phase provided in step (4) preferably contains at least one thickener
  • the method preferably comprises the following further steps:
  • the at least one surface active, ionic polymer is not used in pre-neutralized form or if otherwise necessary, preferably the pH value of the aqueous phase containing the at least one surface active, ionic polymer is suitably adjusted, before the aqueous phase is added to the oil phase or to the obtained emulsion.
  • the pH adjustment ensures that the at least one surface active, ionic polymer is at least partially neutralized.
  • the pH value may be adjusted to 6-7.
  • any suitable base may be used, such as sodium hydroxide, triethanolamine, triisopropanolamine, diethylaminopropylamine, 2- amino-2-methylpropan-l -ol, or trometamol (2-amino-2-hydroxymethyl-propane-l ,3- diol). Trometamol is particularly preferred.
  • any suitable base such as sodium hydroxide, triethanolamine, triisopropanolamine, diethylaminopropylamine, 2- amino-2-methylpropan-l -ol, or trometamol (2-amino-2-hydroxymethyl-propane-l ,3- diol). Trometamol is particularly preferred.
  • the person skilled in the art understands that combinations of the above-mentioned methods of manufacturing are also possible for the manufacture of polymer- stabilized emulsions used according to the invention.
  • the emulsions manufactured according to the above-mentioned methods are preferably charged with 1 to 20 weight-%, preferably 2 to 18 weight-%, more preferably 5 to 15 weight-%, and particularly preferred 10 weight-% of propellant, based on the weight of the foam formulation.
  • the propellant is a pressure-liquefied propellant.
  • the foam formulations according to the present invention can be employed for all cosmetic and dermatological purposes (as a medical product or pharmaceutical composition).
  • the foam formulations may be employed as skin care agent or skin cleaning agent.
  • they may be used as carriers for active agents and may be employed in the medical dermatological field.
  • the formulations may be employed as sunscreen.
  • Many of the solid emulsifiers such as for example titanium dioxide are effective UVA and UVB filters.
  • the present invention is particularly directed to the following preferred embodiment
  • Foam formulation comprising a substantially emulsifier-free emulsion of the oil-in-water type, comprising an oil phase and an aqueous phase, the emulsion comprising at least one surface active, ionic polymer with a molecular weight of more than 5000 g/mol, which stabilizes the emulsion by formation of a gel structure at the oil/water phase interface.
  • Foam formulation comprising a substantially emulsifier-free emulsion of the oil-in-water type, comprising an oil phase and an aqueous phase, wherein the emulsion comprises:
  • At least one surface active, ionic polymer with a molecular weight of more than 5000 g/mol which stabilizes the emulsion by formation of a gel structure at the oil/water phase interface.
  • Foam formulation comprising an emulsion of the oil-in-water type, comprising an oil phase and an aqueous phase, wherein the emulsion comprises an emulsifier system, the emulsifier system consisting substantially of:
  • ionic polymer with a molecular weight of more than 5000 g/mol, which stabilizes the emulsion by formation of a gel structure at the oil/water phase interface.
  • the at least one surface active, ionic polymer further acts as thickener.
  • Foam formulation comprising a substantially emulsifier-free emulsion of the oil-in-water type, comprising an oil phase and an aqueous phase, the emulsion comprising
  • Foam formulation comprising a substantially emulsifier-free emulsion of the oil-in-water type, comprising an oil phase and an aqueous phase, wherein the emulsion comprises: a) at least one solid emulsifier, and
  • Foam formulation comprising an emulsion of the oil-in-water type, comprising an oil phase and an aqueous phase, wherein the emulsion comprises an emulsifier system, the emulsifier system consisting substantially of:
  • acid functional groups are selected from the group consisting of sulfonic acid groups, carboxylic acid groups, phosphoric acid groups, phosphonic acid groups and mixtures thereof.
  • the ionic monomer (Ml) is selected from the group consisting of acrylic acids, methacrylic acids, crotonic acids, maleic acids, fumaric acids, styrene sulfonic acids, vinyl sulfonic acids, vinyl phosphonic acids, allyl sulfonic acids, methallyl sulfonic acids, acrylamido alkylsulfonic acids, which may each be present as free acid, partially or completely neutralized in the form of their salts, preferably the alkali metal salts, alkaline-earth metal salts, ammonium salts or alkanol ammonium salts; or as anhydride, and mixtures thereof, and preferably the ionic monomer (Ml) is selected from the group consisting of acrylic acids, methacrylic acids, and acrylamido alkylsulfonic acids.
  • acrylamido alkylsulfonic acid is partially or completely neutralized and is present as alkali metal salt, alkaline-earth metal salt, ammonium salt or alkanol ammonium salt, preferably as sodium salt or ammonium salt, particularly preferred as ammonium salt.
  • R ⁇ is selected from the group consisting of hydrogen, methyl or ethyl
  • Z is a (Ci-C 8 )-alkylene, that may be unsubstituted or substituted with one or more (Ci-C 4 )-alkyl groups
  • X + is selected from the group consisting of H + , an alkali metal ion, an alkaline-earth metal ion, an ammonium ion, an alkanol ammonium ion, or mixtures thereof, preferably from the group consisting of H + , Na + , NH 4 + , or mixtures thereof.
  • X is selected from the group consisting of H , an alkali metal ion, an alkaline-earth metal ion, an ammonium ion, an alkanol ammonium ion or mixtures thereof, preferably from the group consisting of H + , Na + , NH 4 + or mixtures thereof.
  • the at least one further monomer comprises at least one non-ionic monomer selected from the group consisting of styrenes, chlorostyrenes, di-(Ci-C 30 )- alkylamino styrenes, vinyl chlorides, isoprenes, vinyl alcohols, vinyl methyl ethers, (Ci-C 30 )-carboxylic acid vinyl esters, preferably vinyl acetates and vinyl propionates; acrylic acid esters, methacrylic acid esters, maleic acid esters, fumaric acid esters, crotonic acid esters; in particular linear and branched (C(-C 3 o)-alkyl esters of acrylic acid, methacrylic acid, maleic acid, fumaric acid and crotonic acid; linear and branched (Ci-C 30 )- hydroxyalkyl esters of acrylic acid, methacrylic acid, maleic acid, fumaric acid and crotonic acid;
  • the at least one further monomer comprises at least one non-ionic monomer selected from the group consisting of linear and branched (Q- C 30 )-alkyl esters of acrylic acid or methacrylic acid; linear and branched (Ci-C 30 )-hydroxyalkyl esters of acrylic acid or methacrylic acid;
  • the at least one further monomer comprises at least one non-ionic monomer selected from the group consisting of linear and branched (Ci- C )-hydroxyalkyl esters of acrylic acid or methacrylic acid, preferably hydroxyethyl acrylate; ethoxylated (Ci-C 30 )-alkyl esters of acrylic acid or methacrylic acid having from 1 to 40 ethylene oxide units; preferably beheneth-25-methacrylate; N,N-di-(Ci-C 6 )-alkyl acrylamides, preferably ⁇ , ⁇ -dimethylacrylamides, cyclic and linear N-vinyl carboxylic acid amides having a carbon chain of 2 to 9 carbon atoms, preferably N- vinylpyrrolidone, and mixtures thereof.
  • the at least one further monomer comprises at least one non-ionic monomer selected from the group consisting of linear and branched (Ci- C )-hydroxyalkyl esters of acrylic acid or methacryl
  • the at least one further monomer comprises at least one ionic monomer selected from the group consisting of acrylic acids, methacrylic acids, crotonic acids, maleic acids, fumaric acids, styrene sulfonic acids, vinyl sulfonic acids, vinyl phosphonic acids, allyl sulfonic acids, methallyl sulfonic acids, acrylamido alkylsulfonic acids, which may each be present as free acid, partially or completely neutralized in the form of their salts, preferably the alkali metal salts, alkaline-earth metal salts or ammonium salts; or as anhydride, and mixtures thereof.
  • the at least one further monomer comprises at least one ionic monomer selected from the group consisting of acrylic acids, methacrylic acids, crotonic acids, maleic acids, fumaric acids, styrene sulfonic acids, vinyl sulfonic acids, vinyl phosphonic acids, allyl sulfonic acids,
  • the at least one further monomer comprises an acrylic acid which is present partially or completely neutralized in the form of its alkali metal salts, alkaline-earth metal salts or ammonium salts.
  • the at least one further monomer comprises sodium acrylate.
  • crosspolymer hydroxyethyl acrylate/ sodium acryloyldimefhyltaurate copolymer, sodium acrylate/ sodium acryloyldimefhyltaurate copolymer, and mixtures thereof.
  • acryloyldimethyltaurate/ vinylpyrrolidone copolymer particularly preferred ammonium acryloyldimethyltaurate/ vinylpyrrolidone copolymer.
  • X + is Na + or NH 4 + , preferably NH 4 +
  • n and m are integers which vary independently of each other between 1 to 10.000.
  • the at least one further monomer is selected from the group consisting of cyclic and linear N-vinyl carboxylic acid amides having a carbon chain of 2 to 9 carbon atoms, linear and branched (C
  • Foam formulation according to embodiment 42 wherein the at least one further monomer is selected from the group consisting of cyclic and linear N-vinyl carboxylic acid amides having a carbon chain of 2 to 9 carbon atoms, linear and branched (Ci-C 6 )-alkyl esters of acrylic acid, linear and branched (Ci-C 6 )-alkyl esters of methacrylic acid, and mixtures thereof.
  • the at least one further monomer is selected from the group consisting of cyclic and linear N-vinyl carboxylic acid amides having a carbon chain of 2 to 9 carbon atoms, linear and branched (Ci-C 6 )-alkyl esters of acrylic acid, linear and branched (Ci-C 6 )-alkyl esters of methacrylic acid, and mixtures thereof.
  • Foam formulation according to embodiment 42 or 43 wherein the ionic monomer (Ml) is acrylic acid and the at least one further monomer is a cyclic or linear N-vinyl carboxylic acid amide having a carbon chain of 2 to 9 carbon atoms.
  • the ionic monomer (Ml) is acrylic acid and the at least one further monomer is a cyclic or linear N-vinyl carboxylic acid amide having a carbon chain of 2 to 9 carbon atoms.
  • N-vinyl carboxylic acid amide is N-vinyl pyrrolidone, N-vinyl caprolactame, N-vinyl acetamide, or N-vinyl-N-methylacetamide, preferably N-vinyl pyrrolidone.
  • Foam formulation according to embodiments 42 or 43 wherein the ionic monomer (Ml) is methacrylic acid and the at least one further monomer is selected from one or more, linear or branched (Ci-C 6 )-alkyl esters of acrylic acid or methacrylic acid, preferably from one or more linear or branched (Ci-C 6 )-alkyl esters of acrylic acid, more preferably from one or more of methyl acrylate, ethyl acrylate, n-propyl acrylate, i-propyl acrylate, n-butyl acrylate, i-butyl acrylate, tert-butyl acrylate, and mixtures thereof.
  • the ionic monomer (Ml) is methacrylic acid
  • the at least one further monomer is selected from one or more, linear or branched (Ci-C 6 )-alkyl esters of acrylic acid or methacrylic acid, preferably from one or more linear or branched
  • the at least one surface active ionic polymer comprises acrylic acid/ N-vinyl pyrrolidone copolymer and/or tert-butyl acrylate/ ethyl acrylate/ methacrylic acid terpolymer. 49.
  • Foam formulation according to any one of embodiments 9 to 50 wherein the weight ratio of the ionic monomer (Ml) to the at least one further monomer is from 99: 1 to 1 :99, preferably from 95:5 to 5:95, particularly preferred from 90: 10 to 10:90. 52.
  • Foam formulation according to any one of embodiments 9 to 51 wherein the weight ratio of the ionic monomer (Ml) to the at least one further monomer is from 99: 1 to 1 :99, preferably from 95:5 to 5:95, particularly preferred from 90: 10 to 10:90. 52.
  • copolymer is cross-linked.
  • copolymer contains from 0.001 to 10 weight-%, preferably from 0.01 to 10 weight-% crosslinking agent.
  • crosslinking agent is selected from the group consisting of diallyloxyacetic acid or salts thereof, trimethylol propane triacrylate, trimethylol propane diallyl ether, ethylene glycol dimethacrylate, diethylene glycol diacrylate, tetraethylene glycol diacrylate, methylene
  • the emulsion comprises at least one particulate solid emulsifier, selected from the group consisting of titanium dioxide, silicon dioxide, Fe 2 0 3j zinc oxide, veegum, bentonite and ethyl cellulose, aluminium oxide, calcium carbonate, coal, magnesium oxide, magnesium trisilicate, crystalline fatty acids, crystalline fatty acid esters, crystalline fatty alcohols, polymer lattices such as polystyrenes or polymethacrylates, and polymer- pseudolattices or mixtures thereof.
  • particulate solid emulsifier selected from the group consisting of titanium dioxide, silicon dioxide, Fe 2 0 3j zinc oxide, veegum, bentonite and ethyl cellulose, aluminium oxide, calcium carbonate, coal, magnesium oxide, magnesium trisilicate, crystalline fatty acids, crystalline fatty acid esters, crystalline fatty alcohols, polymer lattices such as polystyrenes or polymethacrylates, and polymer- pseudo
  • the emulsion comprises at least one solid emulsifier selected from the group consisting of crystalline fatty acids, crystalline fatty acid alkyl esters, crystalline fatty alcohols or mixtures thereof.
  • the at least one solid emulsifier comprises a crystalline fatty acid, preferably with a chain length of 10 to 40 carbon atoms.
  • the crystalline fatty acid is a saturated fatty acid, preferably selected from the group consisting of myristic acid, palmitic acid, margaric acid, stearic acid and arachidic acid or mixtures thereof, particularly preferred stearic acid.
  • the at least one solid emulsifier comprises a crystalline fatty alcohol, preferably with a chain length of 10 to 40 carbon atoms.
  • a saturated fatty alcohol preferably selected from the group consisting of myristic alcohol, cetyl alcohol, heptadecanol, stearyl alcohol, cetylstearyl alcohol, eicosanol, or mixtures thereof, particularly preferred cetylstearyl alcohol.
  • Foam formulation according to embodiment 66
  • triglyceride comprises caprylic acid/capric acid triglyceride.
  • the oil phase comprises at least one fatty acid alkyl ester and/or fatty alcohol, preferably selected from the group consisting of decyl oleate, cetearyl isononanoate and 2-octyldodecanol, and mixtures thereof
  • thickener is selected from the group consisting of xanthan gum, sodium polyacrylate, hydroxypropyl methyl cellulose and mixtures thereof.
  • Foam formulation according to any one of the preceding embodiments, wherein the emulsion contains at least one active agent.
  • Foam formulation according to embodiment 72 wherein the active agent is selected from the group consisting of hydroviton, pyrrolidone carboxylic acid and salts thereof, lactic acid and salts thereof, glycerol, sorbitol, propylene glycol, urea, collagen, elastin, silk protein, hyaluronic acid, pentavitin, ceramide, panthenol, niacin, a- tocopherol and esters thereof, vitamin A, vitamin C, galates, polyphenols, panthenol, bisabolol, phytosteroles, glucocorticoids, antibiotics, analgesics, antiphlogistics, antirheumatics, antiallergics, antiparasitics,
  • antipruriginostics antipsoriatics, retinoids, local anaesthetics, therapeutics for the veins, ceratolytics, hyperaemic compounds, coronary therapeutics (nitrates/nitro-compounds), antiviral drugs, cytostatics, hormones, agents promoting wound healing, growth factors, enzyme preparations, insecticides and plant material such as plant extracts of algae, aloe, arnica, barber's rash, comfrey, birch, nettle, calendula, oak, ivy, witch-hazel, henna, hop, camomile, ruscus, peppermint, marigold, rosemary, sage, green tea, tea tree, horse tail, thyme, and walnut or mixtures thereof.
  • Foam formulation according to any one of the preceding embodiments, wherein the foam formulation is a foam cream.
  • Foam formulation according to any one of the preceding embodiments, wherein the foam formulation contains a propellant, preferably a pressure- liquefied propellant.
  • Foam formulation according to embodiment 75 wherein the propellant is selected from the group consisting of N 2 0, propane, butane, i-butane and mixtures thereof.
  • Foam formulation according to any one of the preceding embodiments wherein the foam formulation contains from 1 to 20 weight-%, preferably from 2 to 18 weight-%, more preferably from 5 to 15 weight-% of propellant. 78. Foam formulation according to any one of the preceding embodiments, wherein the foam formulation is present in a pressurized container.
  • a substantially emulsifier-free emulsion of the oil-in-water type comprising an oil phase and an aqueous phase, the emulsion comprising at least one surface active ionic polymer with a molecular weight of more than 5000 g/mol, wherein the ionic polymer is a copolymer comprising as monomer units
  • the ionic polymer is a copolymer comprising as monomer units
  • Method according to embodiment 90 wherein the oil phase provided in step (1) contains at least one thickener, and/or the aqueous phase provided in step (2) contains at least one thickener and/or the method comprises preferably the following further steps:
  • step (3) mixing the further aqueous phase with the emulsion obtained in step (3).
  • Method according to embodiment 92 or 93 wherein the mixing of the further aqueous phase with the emulsion in step (5) is performed at a temperature of from 10 to 30°C, preferably of from 15 to 25°C and particularly preferred at room temperature.
  • Method according to any one of embodiments 90 to 94 wherein the liquid oil phase is provided in step (1) in the form of a clear melt, preferably by heating to a temperature of from 60 to 90°C. 96.
  • Method according to any one of embodiments 90 to 95 wherein the mixing and homogenizing of the aqueous phase with the oil phase in step (3) is performed at a temperature of from 25 to 60°C, preferably of from 30 to 50°C.
  • liquid oil phase provided in step (1) contains at least one solid emulsifier.
  • Method according to any one of embodiments 89 to 97 wherein the emulsion is charged with 1 to 20 weight-%, preferably 2 to 18 weight-%, more preferably 5 to 15 weight-% and particularly preferred 10 weight-% of propellant, based on the weight of the foam formulation.
  • propellant is a pressure-liquefied propellant.
  • phase 1 The ingredients of phase 1 are heated to 70 °C to obtain a clear melt. After cooling 40 °C, phase 1 is emulsified into phase 2, the latter being heated to 40 °C. The mixture is homogenized at 3000 rpm for 5 minutes. After cooling to room temperature, phase 3 is mixed to the obtained emulsion at 1000 rpm.
  • a cream foam is formed upon dispensing the foam formulation from the pressurized container by means of a suitable valve having a foam applicator attached.
  • the following foam qualities are achieved with the formulations of examples Al to A6:
  • the foam stability of which is indicated as "+/-” the foam quality may be converted into a "+” by a higher content of emulsifier-copolymer (in the simultaneous presence of a solid substance in the oil phase).
  • phase 1 The lipid components of phase 1 are heated to 70 °C to obtain a clear melt. After cooling to 40 °C, the two polymers xanthan gum and Cosmedia SP are dispersed in the oil.
  • phase 2 urea, propylene glycol and glycerol are added to the water heated to 40 °C and dissolved therein or blended therewith.
  • the emulsifier- copolymer is added to the aqueous solution or mixture, and brought into solution with stirring.
  • phase 1 is emulsified into phase 2. Subsequently, the emulsion/gel cream is cooled to room temperature.
  • a cream foam is formed upon dispensing the foam formulation from the pressurized container by means of a suitable valve having a foam applicator attached.
  • q.s. quantum satis; trometamol is added in an amount to adjust phase 3 to pH 6-7 2 )
  • the amount of water is chosen so that the weight of phase 3 is 40 g.
  • phase 1 The ingredients of phase 1 are heated to 70 °C to obtain a clear melt. After cooling to 40 °C, phase 1 is emulsified into phase 2, the latter being heated to 40 °C. The mixture is homogenized at 3000 rpm for 5 minutes. After cooling to room temperature, phase 3 (adjusted to pH 6-7) is mixed into the obtained emulsion at 1000 rpm.
  • a cream foam is formed upon dispensing the foam formulation from the pressurized container by means of a suitable valve having a foam applicator attached.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cosmetics (AREA)
  • Polymerisation Methods In General (AREA)
  • Manufacture Of Porous Articles, And Recovery And Treatment Of Waste Products (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
PCT/EP2010/007542 2009-12-10 2010-12-10 Emulsifier-free, polymer-stabilized foam formulations WO2011069674A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CA2783121A CA2783121C (en) 2009-12-10 2010-12-10 Emulsifier-free, polymer-stabilized foam formulations
UAA201208487A UA107003C2 (uk) 2009-12-10 2010-12-10 Пінна композиція, вільна від емульгатора, стабілізована полімером
CN2010800555999A CN102652011A (zh) 2009-12-10 2010-12-10 无乳化剂的聚合物稳定的泡沫制剂
MX2012006619A MX2012006619A (es) 2009-12-10 2010-12-10 Formulaciones de espuma de polimero estabilizado libre de emulsionante.
US13/514,687 US9468590B2 (en) 2009-12-10 2010-12-10 Emulsifier-free, polymer-stabilized foam formulations
EP10787327.5A EP2509565B1 (en) 2009-12-10 2010-12-10 Emulsifier-free, polymer-stabilised foam formulations
PL10787327T PL2509565T3 (pl) 2009-12-10 2010-12-10 Bezemulgatorowe, stabilizowane polimerami preparaty pianowe
ES10787327.5T ES2684304T3 (es) 2009-12-10 2010-12-10 Formulaciones de espuma sin emulgentes y estabilizadas con polímeros
BR112012012934-1A BR112012012934B1 (pt) 2009-12-10 2010-12-10 ''formulações de espuma isentas de emulsificante, estabilizadas com polímero''
KR1020127017936A KR101835712B1 (ko) 2009-12-10 2010-12-10 유화제 무함유, 폴리머-안정화 폼 제제
JP2012542400A JP2013513558A (ja) 2009-12-10 2010-12-10 乳化剤を含まない、ポリマーで安定化された泡沫製剤
EA201200867A EA026509B1 (ru) 2009-12-10 2010-12-10 Не содержащие эмульгатор, стабилизированные полимером пенообразующие препаративные формы
IL220267A IL220267A (en) 2009-12-10 2012-06-07 Polymer-stabilized foam preparations without emulsion material

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28525209P 2009-12-10 2009-12-10
US61/285,252 2009-12-10
EP09015330.5 2009-12-10
EP09015330.5A EP2335675B1 (de) 2009-12-10 2009-12-10 Emulgatorfreie, Polymer-stabilisierte Schaumformulierungen

Publications (1)

Publication Number Publication Date
WO2011069674A1 true WO2011069674A1 (en) 2011-06-16

Family

ID=42144766

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/007542 WO2011069674A1 (en) 2009-12-10 2010-12-10 Emulsifier-free, polymer-stabilized foam formulations

Country Status (15)

Country Link
US (1) US9468590B2 (pl)
EP (2) EP2335675B1 (pl)
JP (1) JP2013513558A (pl)
KR (1) KR101835712B1 (pl)
CN (1) CN102652011A (pl)
BR (1) BR112012012934B1 (pl)
CA (1) CA2783121C (pl)
EA (1) EA026509B1 (pl)
EC (1) ECSP12011953A (pl)
ES (2) ES2537151T3 (pl)
IL (1) IL220267A (pl)
MX (1) MX2012006619A (pl)
PL (2) PL2335675T3 (pl)
UA (1) UA107003C2 (pl)
WO (1) WO2011069674A1 (pl)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140134255A1 (en) * 2011-08-02 2014-05-15 Shiseido Company, Ltd. Oil-In-Water-Type Emulsion Cosmetic
US8857741B2 (en) 2012-04-27 2014-10-14 Conopco, Inc. Topical spray composition and system for delivering the same
WO2022052398A1 (en) * 2020-09-11 2022-03-17 Shandong Benzhen Cosmetics Co., Ltd Surfactant-free foamable oral care composition

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2537151T3 (es) 2009-12-10 2015-06-02 Neubourg Skin Care Gmbh & Co. Kg Formulaciones de espuma estabilizadas con polímeros, libres de emulsionantes
CN102939078B (zh) 2010-06-11 2014-12-24 利奥制药有限公司 含有维生素d类似物和皮质类固醇的药用喷雾剂组合物
AU2014384861B2 (en) 2014-03-03 2016-12-08 Halliburton Energy Services, Inc. Viscosifier polymer for treatment of a subterranean formation
US10113098B2 (en) 2014-12-19 2018-10-30 Halliburton Energy Servives, Inc. Composition including viscosifier polymer and polyamine viscosity modifier for treatment of subterranean formations
US9701882B2 (en) 2014-12-19 2017-07-11 Halliburton Energy Services, Inc. Composition including viscosifier polymer and polyamine viscosity modifier for treatment of subterranean formations
DE102015221568A1 (de) * 2015-11-04 2017-05-04 Beiersdorf Ag Kosmetischer Schaum aus einer Emulsion enthaltend Glycerin und Alkohol
CN106928957B (zh) * 2015-12-31 2019-08-02 北京爱普聚合科技有限公司 一种泡沫压裂用结构型聚合物稳泡剂及其制备方法
FR3046540B1 (fr) * 2016-01-08 2018-03-02 Evergreen Land Limited Formulation aqueuse comprenant une composition lipophile
ES2912275T3 (es) * 2016-08-09 2022-05-25 Univ Liverpool Composiciones oftálmicas
SG11201902759SA (en) * 2016-09-27 2019-05-30 Shiseido Co Ltd Cosmetic raw material using core-corona type microparticles and oil-in-water emulsified cosmetic
DE102017204709A1 (de) 2017-03-21 2018-09-27 Beiersdorf Ag Kosmetischer Schaum enthaltend Wachse und Polyacrylsäurepolymere
US20180280279A1 (en) * 2017-03-31 2018-10-04 L'oreal Soap and surfactant free shave lotion composition
FR3079415B1 (fr) * 2018-03-29 2020-07-24 Coatex Sas Composition cosmetique resistante a l'eau
JP7221010B2 (ja) * 2018-08-10 2023-02-13 株式会社 資生堂 ゲル粒子及びそれを含む皮膚外用剤
US11679071B2 (en) * 2020-05-13 2023-06-20 Peptonic Medical Ab Urogenital cleansing composition
CN114957539B (zh) * 2022-04-19 2023-05-30 万华化学集团股份有限公司 由季铵盐型gemini乳化剂制备多孔抑菌材料的方法、多孔抑菌材料及应用
CN115025002A (zh) * 2022-06-24 2022-09-09 广东博然堂生物科技有限公司 一种不含乳化剂的0/w型分散体系及其制备方法

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3330730A (en) * 1962-08-03 1967-07-11 Colgate Palmolive Co Pressurized emulsion quick breaking foam compositions
EP0835647A1 (fr) * 1996-10-14 1998-04-15 L'oreal Crème auto-moussante
DE19825961A1 (de) * 1998-06-10 1999-12-16 Goldwell Gmbh Aerosolschaumzusammensetzung zum Konditionieren von menschlichen Haaren
DE19907715A1 (de) * 1999-02-23 2000-08-24 Schwarzkopf Gmbh Hans Zubereitungen zur Behandlung keratinischer Fasern
EP1069142A1 (de) 1999-07-15 2001-01-17 Clariant GmbH Wasserlösliche Polymere und ihre Verwendung in kosmetischen und pharmazeutischen Mitteln
EP1116733A1 (de) 2000-01-11 2001-07-18 Clariant GmbH Wasserlösliche oder wasserquellbare vernetzte Copolymere
EP1138703A1 (fr) 2000-03-29 2001-10-04 Societe D'exploitation De Produits Pour Les Industries Chimiques, S.E.P.P.I.C. Nouveau polymère, procédé de préparation, utilisation comme épaississant et/ou émulsionnant et composition en comprenant
WO2003022236A1 (en) 2001-09-12 2003-03-20 Unilever Plc Thickened cosmetic compositions comprising a taurate copolymer
DE10162840A1 (de) 2001-12-20 2003-07-03 Beiersdorf Ag Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an wasserlöslichen UV-Filtersubstanzen und Benzoxazol-Derivaten
EP1352639A1 (de) 2002-04-11 2003-10-15 Beiersdorf Aktiengesellschaft Kosmetische und dermatologische Formulierungen mit einem Gehalt an Hydroxybenzophenonen und einem oder mehreren vorgelatinisierten, quervernetzten Stärkederivaten
WO2004017930A1 (de) 2002-08-23 2004-03-04 Beiersdorf Ag Dünnflüssige kosmetische oder dermatologische zubereitungen von typ öl-in-wasser
US20050074414A1 (en) * 2002-10-25 2005-04-07 Foamix Ltd. Penetrating pharmaceutical foam
WO2006044193A2 (en) 2004-10-14 2006-04-27 Isp Investments Inc. Rheology modifier/hair styling resin
WO2006065530A2 (en) * 2004-12-17 2006-06-22 Johnson & Johnson Consumer Companies, Inc. Cleansing compositions comprising polymeric emulsifiers and methods of using same
WO2008087326A2 (fr) 2006-12-27 2008-07-24 Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic Nouveau polymere en poudre comportant un monomere tensioactif, procede pour sa preparation et utilisation comme epaississant
WO2008138894A2 (de) 2007-05-10 2008-11-20 Neubourg Skin Care Gmbh & Co. Kg Tensidfreie schaumformulierungen
WO2008155389A2 (de) 2007-06-19 2008-12-24 Neubourg Skin Care Gmbh & Co. Kg Dms (derma membrane structure) in schaum-cremes

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2968628A (en) 1958-10-17 1961-01-17 Shulton Inc Propellant composition
JPS5112591B1 (pl) 1970-12-28 1976-04-20
US3793464A (en) 1971-04-26 1974-02-19 Ici America Inc Process for preparing aqueous emulsion of proteinaceous food products
US3970584A (en) 1973-02-14 1976-07-20 S. C. Johnson & Son, Inc. Aerosol package containing a foam-forming emulsion and propellent system
FR2487356A1 (fr) 1980-07-25 1982-01-29 Oreal Emulsions stables obtenues a partir d'un agent emulsionnant naturel stabilise par du suc d'aloes
US4411926A (en) 1982-02-04 1983-10-25 General Foods Corporation Stabilizer for frozen foamed emulsions and method therefore
US4661340A (en) 1983-06-06 1987-04-28 Interkemia Vegyipari Gazdasagi Tarsasag Quail egg based stabilized foam compositions for cosmetic purposes
US4551480A (en) 1983-06-21 1985-11-05 Stiefel Laboratories, Inc. Compositions for the treatment of psoriasis
DE3330628C2 (de) 1983-08-25 1985-11-07 Schülke & Mayr GmbH, 2000 Norderstedt Hautschutz- und -pflegelotion
US4515810A (en) 1983-10-06 1985-05-07 American Cyanamid Company Composition of matter
US4622074A (en) 1984-03-01 1986-11-11 Miyoshi Kasei Co., Ltd. Pigments and extender pigments which are surface-treated with hydrogenated lecithin, and cosmetics containing the same
EP0194097B1 (en) 1985-03-01 1990-04-25 The Procter & Gamble Company Mild cleansing mousse
DE3628531A1 (de) 1986-08-22 1988-02-25 Merz & Co Gmbh & Co Verschaeumbare cremes
KR880005918A (ko) 1986-11-10 1988-07-21 원본미기재 안정하며 빨리 분해되는 국소피부조성물
US5445813A (en) 1992-11-02 1995-08-29 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
DE4238860A1 (de) 1992-11-19 1994-05-26 Medicon Gmbh Hautschutzmittel zum Schutz der menschlichen Haut
US5616746A (en) 1993-04-15 1997-04-01 L'oreal Use in cosmetics of lipophilic derivatives of amino deoxyalditols, cosmetic compositions containing them, and novel alkyl carbamates
ZA946016B (en) 1993-08-30 1996-02-12 Colgate Palmolice Company An aerosol shaving cream formulation
DE4420625C1 (de) 1994-06-14 1995-11-02 Beiersdorf Ag Wirkstoffkombination mit einem Gehalt an Glycerylalkylethern und kosmetische und dermatologische Zubereitungen, solche Wirkstoffkombinationen enthaltend
US5525588A (en) 1994-09-14 1996-06-11 Elzabeth Arden Co. Cosmetic composition
US5540853A (en) 1994-10-20 1996-07-30 The Procter & Gamble Company Personal treatment compositions and/or cosmetic compositions containing enduring perfume
US5653970A (en) 1994-12-08 1997-08-05 Lever Brothers Company, Division Of Conopco, Inc. Personal product compositions comprising heteroatom containing alkyl aldonamide compounds
GB9504265D0 (en) 1995-03-03 1995-04-19 Medeva Plc Corticosteroid-containing pharmaceutical composition
JP3432979B2 (ja) 1995-11-17 2003-08-04 花王株式会社 化粧料
GB9602111D0 (en) 1996-02-02 1996-04-03 Unilever Plc Personal care composition
US6015574A (en) 1997-06-09 2000-01-18 L'oreal Lipophilic carrier systems
AU9162498A (en) 1997-08-18 1999-03-08 Neubourg, Stephanie Foaming skin cream, uses thereof and a method for producing the same
AUPP060097A0 (en) 1997-11-28 1998-01-08 Commonwealth Scientific And Industrial Research Organisation Adjuvant system for enhanced response
TW592713B (en) 1998-05-11 2004-06-21 Ciba Sc Holding Ag Use of nanodispersions in cosmetic end formulations
FR2780278B1 (fr) 1998-06-24 2001-01-19 Oreal Composition conditionnante et detergente et utilisation
AUPP583198A0 (en) 1998-09-11 1998-10-01 Soltec Research Pty Ltd Mousse composition
DE19842730A1 (de) 1998-09-18 2000-03-23 Beiersdorf Ag Emulgatorfreie feindisperse Systeme vom Typ Öl-in-Wasser und Wasser-in-Öl
DE19851890B4 (de) 1998-11-11 2005-02-10 Ladoco Ag Druckbehälter
DE19859427A1 (de) 1998-12-22 2000-06-29 Beiersdorf Ag Kosmetische oder pharmazeutische lecithinhaltige Gele oder niedrigviskose, lecithinhaltige O/W-Mikroemulsionen
GB9908593D0 (en) 1999-04-16 1999-06-09 Quest Int Dental compositions containing boswellia extracts
FR2792545B1 (fr) 1999-04-20 2001-06-01 Oreal Composition foisonnee, son procede de fabrication et son utilisation notamment comme composition cosmetique
DE19923648A1 (de) * 1999-05-22 2000-11-23 Beiersdorf Ag Kosmetische und dermatologische Hydrodispersion mit einem Gehalt an Bornitrid
GB9929969D0 (en) 1999-12-17 2000-02-09 Unilever Plc Packaged liquid cleansing composition
FR2802805B1 (fr) 1999-12-22 2002-08-16 Cognis Deutschland Gmbh Melanges cosmetiques a base d'agents emulsionnants et de composes huileux, aptes a la formation de phases lamellaires liquides
KR100884845B1 (ko) 2000-02-25 2009-02-20 쿠스 게엠베하 노화 및/또는 스트레스성 피부용 화장용 조성물
ES2218401T3 (es) 2000-03-28 2004-11-16 Birken Gmbh Emulsion que contiene un extracto de plantas que incluye triterpeno, procedimiento para la preparacion de la emulsion asi como para la obtencion del extracto de plantas.
DE10033414B4 (de) 2000-07-08 2004-02-19 Wella Aktiengesellschaft Klares, zweiphasiges, schaumbildendes Aerosol-Haarpflegeprodukt
WO2002038638A1 (de) 2000-11-10 2002-05-16 Basf Aktiengesellschaft Acrylatpolymerisate auf basis von tert.butylacrylat und/oder tert.-butylmethacrylat
WO2002085921A2 (de) 2001-03-01 2002-10-31 Johann Jauch Einfaches verfahren zur synthese von boswelliasäuren und derivaten davon
FR2825629A1 (fr) 2001-06-11 2002-12-13 Oreal Composition de nettoyage de la peau
FR2827766A1 (fr) 2001-07-27 2003-01-31 Oreal Composition a base de vesicules lamellaires lipidiques incorporant au moins un compose a base de dhea
US20030083210A1 (en) 2001-08-24 2003-05-01 Unilever Home And Personal Care Usa, Division Of Conopco, Inc. Lamellar post foaming cleansing composition and dispensing system
DE10146500A1 (de) 2001-09-21 2003-04-17 Beiersdorf Ag Kosmetische und/oder dermatologische Wirkstoffkombination
DE10148392A1 (de) 2001-09-29 2003-04-30 Beiersdorf Ag Kosmetische Reinigungsschäume
DE10161171A1 (de) 2001-12-13 2003-06-18 Beiersdorf Ag Talkumhaltige kosmetische Reinigungsemulsionen
US20030129213A1 (en) 2001-12-26 2003-07-10 Gonzalez Anthony D. Meta-stable insect repellent emulsion composition and method of use
US6517816B1 (en) 2001-12-26 2003-02-11 Avon Products, Inc. Sunscreen emulsion composition and method of use
US20030211069A1 (en) * 2002-05-09 2003-11-13 The Procter & Gamble Company Rinsable skin conditioning compositions
DE10231062A1 (de) 2002-07-10 2004-01-22 Beiersdorf Ag Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an hydrophobisierten Acrylamidomethylpropylsulfonsäure-Polymeren
DE10237281A1 (de) 2002-08-14 2004-03-04 Birken Gmbh Vorrichtung zur kontinuierlichen Extraktion von Extraktstoffen aus Pflanzen
KR100489701B1 (ko) 2002-10-09 2005-05-16 주식회사 태평양 고농도의 트리터페노이드를 함유하는 미소화 리포좀 및 그제조방법
AT501699B1 (de) 2002-10-31 2008-05-15 Merz Pharma Gmbh & Co Kgaa Verschäumbare zusammensetzung auf basis einer o/w- emulsion, deren herstellung und deren verwendung
JP2004331610A (ja) 2003-05-09 2004-11-25 Taiyo Kagaku Co Ltd 油状泡沫性ｕｖケア化粧料組成物
JP2005002030A (ja) 2003-06-11 2005-01-06 Pola Chem Ind Inc フォーム状のエアゾール化粧料
DE10354053A1 (de) 2003-11-17 2005-06-16 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen zur Applikation mit Spendersystemen
ZA200507017B (en) 2004-02-04 2007-03-28 Foamix Ltd Cosmetic and pharmaceutical foam with solid matter
WO2005080451A1 (en) 2004-02-19 2005-09-01 The Lubrizol Corporation Improviong the lipophilic properties of 2-acrylamido-2-methylpropanesulfonic acid
US20060029657A1 (en) 2004-03-26 2006-02-09 Stiefel Laboratories, Inc. Topical skin protectant compositions
US20050265936A1 (en) 2004-05-25 2005-12-01 Knopf Michael A Cleansing foaming sunscreen lotion
DE102004030044A1 (de) 2004-06-22 2006-01-12 Birken Gmbh Triterpenhaltiger Oleogelbildner, triterpenhaltiges Oleogel und Verfahren zur Herstellung eines triterpenhaltigen Oleogels
WO2006003981A1 (ja) 2004-06-30 2006-01-12 Fuji Oil Company, Limited 水中油型乳化物およびこれを用いた食品の製造方法
US20060057075A1 (en) 2004-08-02 2006-03-16 Moshe Arkin Pharmaceutical and cosmeceutical wash-off mousse shampoo compositions, processes for preparing the same and uses thereof
DE102004039212A1 (de) 2004-08-12 2006-03-02 Wacker-Chemie Gmbh Rheologiesteuerung von Pickering-Emulsion durch Elektrolyte
JP4722434B2 (ja) * 2004-08-31 2011-07-13 株式会社ダイゾー 発泡性エアゾール組成物
WO2006050158A2 (en) 2004-10-29 2006-05-11 Jan Glinski Hair and skin protecting compositions based on esters or ethers of betulin
EP1700825A1 (de) 2004-12-23 2006-09-13 Degussa AG Oberflächenmodifizierte, strukturmodifizierte Titandioxide
JP2007008853A (ja) 2005-06-30 2007-01-18 Pola Chem Ind Inc エアゾル化粧料
US9089493B2 (en) 2005-09-16 2015-07-28 The Procter & Gamble Company Skin care composition
US20070134174A1 (en) 2005-11-03 2007-06-14 Christopher Irwin Personal care composition
GB0604535D0 (en) 2006-03-07 2006-04-12 Sndv Sprl Betulonic acid derivatives
DE102006020582A1 (de) 2006-05-03 2007-11-15 Gesellschaft zur Förderung der Krebstherapie e.V. Verfahren zur Herstellung einer triterpensäurehaltigen wässrigen Lösung, triterpensäurehaltige wässrige Lösung und deren Verwendung
DE102006038471A1 (de) 2006-08-17 2008-04-10 Wala-Heilmittel Gmbh Platanencreme, Verfahren zu ihrer Herstellung und Verwendung
CL2008000037A1 (es) 2007-01-16 2008-10-10 Bayer Consumer Care Ag Solucion coloidal que comprende al menos un ingrediente activo, al menos una molecula formadora de membrana y al menos un componente espumante; procedimiento para fabricar la solucion coloidal; y su uso para tratar trastornos dermatologicos.
DE102007061969A1 (de) * 2007-12-21 2008-07-17 Clariant International Limited Wasserlösliche oder wasserquellbare Polymere auf Basis von Salzen der Acryloyldimethyltaurinsäure oder ihrer Derivate, deren Herstellung und deren Verwendung als Verdicker, Stabilisator und Konsistenzgeber
DE102008059445A1 (de) 2008-11-27 2010-06-02 Henkel Ag & Co. Kgaa Schäumende Emulsionen mit Emulgatorkombination
US10568859B2 (en) 2009-02-25 2020-02-25 Mayne Pharma Llc Topical foam composition
ES2537151T3 (es) 2009-12-10 2015-06-02 Neubourg Skin Care Gmbh & Co. Kg Formulaciones de espuma estabilizadas con polímeros, libres de emulsionantes
US20110144578A1 (en) 2009-12-11 2011-06-16 Stephen Pacetti Hydrophobic therapueutic agent and solid emulsifier coating for drug coated balloon
PL2363108T3 (pl) 2010-03-02 2018-04-30 Neubourg Skin Care Gmbh & Co. Kg Formulacje piankowe zawierające co najmniej jeden triterpenoid

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3330730A (en) * 1962-08-03 1967-07-11 Colgate Palmolive Co Pressurized emulsion quick breaking foam compositions
EP0835647A1 (fr) * 1996-10-14 1998-04-15 L'oreal Crème auto-moussante
DE19825961A1 (de) * 1998-06-10 1999-12-16 Goldwell Gmbh Aerosolschaumzusammensetzung zum Konditionieren von menschlichen Haaren
DE19907715A1 (de) * 1999-02-23 2000-08-24 Schwarzkopf Gmbh Hans Zubereitungen zur Behandlung keratinischer Fasern
EP1069142A1 (de) 1999-07-15 2001-01-17 Clariant GmbH Wasserlösliche Polymere und ihre Verwendung in kosmetischen und pharmazeutischen Mitteln
EP1116733A1 (de) 2000-01-11 2001-07-18 Clariant GmbH Wasserlösliche oder wasserquellbare vernetzte Copolymere
EP1138703A1 (fr) 2000-03-29 2001-10-04 Societe D'exploitation De Produits Pour Les Industries Chimiques, S.E.P.P.I.C. Nouveau polymère, procédé de préparation, utilisation comme épaississant et/ou émulsionnant et composition en comprenant
WO2003022236A1 (en) 2001-09-12 2003-03-20 Unilever Plc Thickened cosmetic compositions comprising a taurate copolymer
DE10162840A1 (de) 2001-12-20 2003-07-03 Beiersdorf Ag Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an wasserlöslichen UV-Filtersubstanzen und Benzoxazol-Derivaten
EP1352639A1 (de) 2002-04-11 2003-10-15 Beiersdorf Aktiengesellschaft Kosmetische und dermatologische Formulierungen mit einem Gehalt an Hydroxybenzophenonen und einem oder mehreren vorgelatinisierten, quervernetzten Stärkederivaten
WO2004017930A1 (de) 2002-08-23 2004-03-04 Beiersdorf Ag Dünnflüssige kosmetische oder dermatologische zubereitungen von typ öl-in-wasser
US20050074414A1 (en) * 2002-10-25 2005-04-07 Foamix Ltd. Penetrating pharmaceutical foam
WO2006044193A2 (en) 2004-10-14 2006-04-27 Isp Investments Inc. Rheology modifier/hair styling resin
WO2006065530A2 (en) * 2004-12-17 2006-06-22 Johnson & Johnson Consumer Companies, Inc. Cleansing compositions comprising polymeric emulsifiers and methods of using same
WO2008087326A2 (fr) 2006-12-27 2008-07-24 Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic Nouveau polymere en poudre comportant un monomere tensioactif, procede pour sa preparation et utilisation comme epaississant
WO2008138894A2 (de) 2007-05-10 2008-11-20 Neubourg Skin Care Gmbh & Co. Kg Tensidfreie schaumformulierungen
WO2008155389A2 (de) 2007-06-19 2008-12-24 Neubourg Skin Care Gmbh & Co. Kg Dms (derma membrane structure) in schaum-cremes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Fiedler Lexikon der Hilfsstoffe", EDITIO CANTOR VERLAG, pages: 97 - 121
"Pflegekosmetik", WISSENSCHAFTLICHE VERLAGSGESELLSCHAFT MBH, pages: 151 - 159
ANONYM: "Taking care of your sensory innovations, Aristoflex AVC and Aristoflex HMB", INTERNET CITATION, 2003, XP002372730, Retrieved from the Internet <URL:http://www.clariant-surfactants.com/fun/e2wtools.nsf/vwLookupDownload s/Taking_care_of_your_Sensory_Innovations_-_Aristoflex_-_2003:pdf/$FI LE/Taking_care_of_your_Sensory_Innovations_-_Aristoflex_-_2003.pdf> [retrieved on 20060316] *
LOEFFLER ET AL: "A new ph stable polymer for gels and o/w emulsions", SOFW-JOURNAL SEIFEN, OELE, FETTE, WACHSE, VERLAG FUR CHEMISCHE INDUSTRIE, AUGSBURG, DE, vol. 128, 1 January 2002 (2002-01-01), pages 46 - 52, XP009128608, ISSN: 0942-7694 *
MYERS D.: "Polymers at Interfaces, in Meyers D.: Surfaces, interfaces and colloids", 1991, VHC PUBLISHERS NEW YORK, pages: 283 - 297

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140134255A1 (en) * 2011-08-02 2014-05-15 Shiseido Company, Ltd. Oil-In-Water-Type Emulsion Cosmetic
EP2740462A4 (en) * 2011-08-02 2015-07-22 Shiseido Co Ltd OIL-IN-WATER emulsified cosmetic
US8857741B2 (en) 2012-04-27 2014-10-14 Conopco, Inc. Topical spray composition and system for delivering the same
US9751097B2 (en) 2012-04-27 2017-09-05 Conopco, Inc. Topical spray composition to benefit skin
WO2022052398A1 (en) * 2020-09-11 2022-03-17 Shandong Benzhen Cosmetics Co., Ltd Surfactant-free foamable oral care composition

Also Published As

Publication number Publication date
PL2335675T3 (pl) 2015-08-31
IL220267A (en) 2016-03-31
US9468590B2 (en) 2016-10-18
BR112012012934A2 (pt) 2016-10-04
ES2684304T3 (es) 2018-10-02
MX2012006619A (es) 2012-06-25
IL220267A0 (en) 2012-07-31
ES2537151T3 (es) 2015-06-02
JP2013513558A (ja) 2013-04-22
CA2783121C (en) 2019-03-26
EP2335675A1 (de) 2011-06-22
EP2335675B1 (de) 2015-02-18
CN102652011A (zh) 2012-08-29
EP2509565A1 (en) 2012-10-17
US20120244093A1 (en) 2012-09-27
EA026509B1 (ru) 2017-04-28
ECSP12011953A (es) 2012-07-31
KR20120104312A (ko) 2012-09-20
KR101835712B1 (ko) 2018-03-07
PL2509565T3 (pl) 2018-12-31
EP2509565B1 (en) 2018-05-30
EA201200867A1 (ru) 2012-12-28
UA107003C2 (uk) 2014-11-10
BR112012012934B1 (pt) 2018-02-06
CA2783121A1 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
US9468590B2 (en) Emulsifier-free, polymer-stabilized foam formulations
US20220110842A1 (en) DMS (derma membrane structure) in Foam Creams
US20220193460A1 (en) Surfactant-free foam formulations
DK2542207T3 (en) Foam formulations containing at least one triterpenoid
US20220378671A1 (en) Foam Formulations Containing at Least One Triterpenoid

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080055599.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10787327

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2012542400

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2783121

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 220267

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 13514687

Country of ref document: US

Ref document number: MX/A/2012/006619

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010787327

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: A201208487

Country of ref document: UA

Ref document number: 201200867

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20127017936

Country of ref document: KR

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012012934

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012012934

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20120530